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ABSTRACT

A NEW APPROACH TO DRIED BLOOD SPOT ANALYSIS FOR NEWBORN SCREENING USING HIGH
RESOLUTION LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY
By John H. Miller IV, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2012
Major Director: H. Thomas Karnes, Ph.D. Professor Department of Pharmaceutics, School of
Pharmacy
The primary purpose of newborn screening is to quickly identify children that are at risk
of having a specific disorder in order to start treatment, prevent early death and reduce the
chances of permanent physical or mental damage. The current and widely accepted approach
used for identification of metabolism disorders involves a flow injection analysis with mass
spectrometry detection of acylcarnitines and amino acids. Although this approach is widely
accepted and has shown to be sufficient for identification of multiple metabolism disorders the
method is not fully quantitative and results often have to be confirmed by second-tier tests.
The primary focus of this research was to improve the accuracy and selectivity of this
screening method by employing a high resolution chromatographic separation for the
combined analysis of twelve acylcarnitines and seven amino acids. This method is an
improvement over the current methodology allowing for separation of key isomers that are
diagnostic for different metabolism disorders, reducing the need for multiple second-tier tests
to confirm results and shortening the time to diagnosis.
xiv

In order to further improve the efficiency of newborn screening we developed an inline desorption device, which allows for direct analysis of DBS eliminating the need for punching
disks from the filter paper cards. Our device was the first published paper that demonstrated
the ability to directly analyze dried blood spots, without the need for any offline sample
processing. Using this device, we validated a method to quantify biomarkers related to Maple
Syrup Urine Disease, a disorder that requires a second-tier test for confirmation.
To further improve the accuracy of dried blood spot analysis we evaluated a technique
to correct the sample volume in low and high hematocrit samples. The level of hematocrit in
blood spotted on filter paper cards affects the volume of sample analyzed, leading to errors in
accuracy. Diffuse reflectance was used to relate differences in sample hematocrit on dried
blood spots. We validated our technique with eighteen donor samples at various levels of
hematocrit. Correcting sample volume for hematocrit showed improved precision and accuracy
over the standard approach, ultimately reducing the potential to misidentify samples.

xv

CHAPTER 1

BACKGROUND TO NEWBORN SCREENING DRIED BLOOD SPOT
ANALYSIS

1.1 Introduction
1.1.1 Background to newborn screening
Since the late 1960’s it has been a requirement that all state laboratories screen
newborns for inherited metabolism disorders (Sahai & Marsden, 2009). Initially, the state
laboratories screened for just one disorder, phenylketonuria (PKU), but gradually additional
tests were added to the screening panel as they were identified. The primary purpose of
implementing newborn screening testing was to quickly identify children that were at risk of
having a specific disorder in order to start treatment, prevent early death and reduce the
chances of permanent physical or mental damage. The cost of screening every newborn was
justified by the ability to save lives by early diagnosis and treatment versus the expenses
associated with long term health effects of untreated babies (Millington, 2005). Current
screening methods are able to identify as many as 40 different disorders from a single sample
(Chace, Kalas, & Naylor, 2003; Sweetman, 2001). Blood is collected from each newborn within
the first week of life using the same technique developed for the analysis of PKU by Robert
Guthrie (Guthrie & Susi, 1963). The newborn’s heel is pricked and the blood is spotted on filter
paper cards, allowed to dry and sent to state laboratories for testing. Several different tests are

1

performed on each sample; some tests require separate analysis for identification of specific
disorders. Acylcarnitines and amino acids, markers for a variety of metabolism disorders, are
typically screened in a single analysis employing flow injection with mass spectrometry
detection.
Acylcarnitines are diagnostic markers for both fatty acid oxidation defects and organic
acid disorders. Carnitine (C0) plays an essential role in the transport of fatty acids to the
mitochondrial for the production of energy (Sahai & Marsden, 2009). The acylcarnitine
nomenclature is based on the chain length of the fatty acid attached to C0, for example a C6 is
the base carnitine attached to a six carbon fatty acid. Structures with unsaturated fatty acid are
identified as C6:1 where the 1 indicates a single unsaturated bond. Dicarboxylic fatty acids and
hydroxylated fatty acid species are represented by “-DC” and “-OH” respectively. The
formation of an acylcarnitine is show in Figure 1.1. where “R” represents the long chain fatty
acid that binds with C0.

Carnitine (C0)
H3C

H2
C
+

N

Acylcarnitine

H2
C

O

H

H3C

CH

H3C
CH3

OH

Fatty Acid

O

N+

H2
C

O

CH

H3C

O

+

H2
C

CH3
O

O

O

C

OH

R

C

R

Figure 1.1: Reaction of free carnitine with a fatty acid to produce an acylcarnitine

2

H

When there is a deficiency in an enzyme specific to the metabolism of fatty acids, it
results in an increase in blood levels of acylcarnitines (Sahai & Marsden, 2009). Since the
enzymes are selective based on the chain length, the enzyme responsible for a disorder can be
identified based on elevation of specific acylcarnitines. Elevated levels of C6, C8 and C10 are an
indication of medium chain acyl CoA dehydrogenase deficiency (MCAD) (Sahai & Marsden,
2009). Elevated C16-OH, C16 and C18:1-OH are an indication long-chain L-hydroxyacyl-CoA
dehydrogenase deficiency (LCHAD), and elevated C14, C14:1 and C16 are indications of very
long chain acyl-CoA dehydrogenase deficiency (VLCAD) (Sahai & Marsden, 2009).
Organic acid disorders arise from impairment of enzymes responsible for the breakdown
of amino acids prior to the citric acid cycle (Sahai & Marsden, 2009). As a consequence excess
levels of short chain organic acids are formed and conjugate with carnitine. Several organic
acid disorders involving vitamin B12 result in elevated levels of Propionylcarnitine (C3) (Sahai &
Marsden, 2009). Other enzyme deficiencies in the metabolism of amino acids will result in
elevated levels of specific amino acids. Phenylketonuria (PKU) is a classical amino acid disorder
in which there is a deficiency in the enzyme responsible for the metabolism of phenylalanine
(Sahai & Marsden, 2009). This results in abnormally high levels of phenylalanine, which can
cause mental retardation if untreated.
Newborn screening methods typically screen for six to eleven amino acids and nine to
twenty acylcarnitines. Positive samples are flagged for clinical diagnosis, in which an
experienced clinician analyzes the mass spectral data and starts an intervention process with
the primary care physician and parents. Diagnosis for a specific disorder requires testing of
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additional blood and urine samples using a quantitative technique and chromatographically
separates the analytes by either gas chromatography or high performance liquid
chromatography. Additional markers are analyzed, such as urinary organic acids, for clinical
diagnosis of certain disorders. Clinical diagnoses tests are typically conducted by independent
laboratories which results in additional time and expense to determine the health of the child.
Once the child is identified as having a specific disorder, the exact nature of the deficiency is
evaluated by testing the level of enzyme activity or gene sequencing. A typical test for enzyme
activity requires profiling the metabolism of a specific analyte in the presence of an enzyme
(Wolf, Grier, Allen, Goodman, & Kien, 1983). Although there are some colorimetric tests that
can be employed at newborn screening centers they are not fully quantitative and often have
to be confirmed by a second laboratory. Gene sequencing is more complex and requires a
second sample to be taken from the newborn (Tiranti et al., 2004). The samples are usually
analyzed using a Western Blot approach along with gel electrophoresis to identify specific
differences in the genome.
1.1.2 Current methodology
There are two widely used approaches in newborn screening for acylcarnitines and
amino acids. The original and widely accepted method requires the analytes to be derivatized
prior to analysis and a more recent approach does not require derivatization. Both techniques
allow for identification of several different metabolism disorders in a single analysis. The
original technique used by most state laboratories was developed at Duke University and
involves the derivatization of the carboxylic acid functional group with n-butanol and
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hydrochloric acid to form butyl esters (Millington, Kodo, Norwood, & Roe, 1990). The final
extracts are analyzed by flow injection analysis (Figure 1.2). Flow injection implies that the
sample is injected without chromatographic separation; instead, the sample is injected into the
flow path of the mobile phase, which carries the plug of sample to the mass spectrometer. The
flow rate is reduced prior to the sample reaching the mass spectrometer which improves the
sensitivity of the method by broadening the elution plug so that the signal can be averaged over
a longer time period. Flow injection analysis can be done rapidly in 2-5 minutes, allowing for
hundreds of samples to be analyzed in a single day (Sweetman, 2001).

Normalized Response

Normalized Response

Precursor Ion Scan m/z 85

Figure 1.2: Flow injection analysis for an extracted dried blood spot sample derivatized with
n-butanol with insert showing the mass spectra for acylcarnitines analyzed by precursor ion
scan for the production of 85 m/z
5

The mass spectral analysis can be very complex; however, most laboratories use
specialized software to help identify and quantify the analytes of interest. Also, there is no
separation between the analytes and matrix components which could affect the quantitation of
some analytes, especially for compounds that do not have labeled internal standards. For
analysis of butylated acylcarnitines, the mass spectral data is collected for positive precursor
ions of the 85 m/z production. Under these conditions the mass spectrometer allows all ions to
pass through the first quadrupole and into the collision cell. The ions are fragmented and only
ions with 85 m/z pass through the third quadrupole and associated precursor ion from the first
quadrupole is identified. The derivatized amino acids are analyzed in a similar fashion, typically
monitoring the neutral loss of 102 m/z. A neutral loss scan function only allows specific ions
that lose a designated mass to pass through to the third quadrupole. In scan mode the
instrument has to ramp the voltage applied to the quadrupole in a specified time to filter ions
from low to high mass to charge (m/z). Although this allows for multiple compounds to be
detected in a single scan it results in lower sensitivity since the time that the mass spectrometer
is detecting an individual mass is a fraction of the scan time. An alternative approach is used to
improve the sensitivity for difficult to detect compounds is called multiple reaction monitoring
(MRM). In this technique the mass spectrometer monitors a specific molecular mass and a
specific fragment ion in a specified dwell time. Multiple reaction monitoring provides the best
sensitivity for an analyte since the mass spectrometer does not need to scan across a series of
masses. Figure 1.3 shows a schematic of mass spectrometer and the different scanning modes
used.
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Figure 1.3: Schematic of a triple quadrupole mass spectrometer with descriptions of different scan modes used by newborn
screening for analysis of amino acids and acylcarnitines

1.1.3 Quantification of acylcarnitines and amino acids
Quantification of amino acids and acylcarnitines is based on the response factors
determined using isotopically labeled internal standards. Dried blood spots are extracted in a
solution containing isotopically labeled internal standards at known concentrations. In the
derivatization based screening method the internal standards are also derivatized during the
sample preparation to form their butyl esters. The response of the internal standard is used to
determine the concentration of the analyte based on Equation 1.1 where the response factor is
either previously determined or assumed to be equal to one. It is recommended that the
response factors be determined prior to analysis using Equation 1.2 in order to more accurately
quantify each analyte. However, most laboratories set cut-off values independently based on
response of normal samples and set a cut-off above this range to identify abnormal samples.
Although, this has been proven to be acceptable for screening there are potential problems
with using a single point response factor for quantitating samples. This technique assumes that
the response of the internal standard is equivalent to the response of the analyte and that the
analyte and internal standard are equally affected by matrix suppression or enhancement,
however this is not always true (Trufelli et al., 2011).

Equation 1.1: Conventional calculation for concentration for analytes extracted from dried
blood spots
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Equation 1.2: Response factor determination for external solutions

1.1.4 Issues associated with newborn screening
Although there are several advantages to using this method for screening, there are also
several inherent problems. The method primarily used but most state laboratories require
multiple extraction steps including derivatization and multiple evaporation steps.
Derivatization has been employed to improve sensitivity of some compounds, but there are
issues as to the efficiency of the derivatization for others (Sapp et al., 2007). Hydrochloric acid
used in the derivatization step is caustic, hazardous and destroys laboratory equipment with
prolonged exposure. Even though the flow injection analysis allows for hundreds of samples to
be analyzed in a single day, it lacks the selectivity to differentiate between disorders associated
with isobaric analytes. The screening method is not fully quantitative and relies on individual
laboratory cut-off values to determine test positive samples. Another concern is the volume of
sample analyzed has been shown to be affected by differences in hematocrit (Mei et al., 2001).
Hematocrit affects the diffusion properties of blood on the filter paper. Samples with high
hematocrit will not diffuse as much as samples with low hematocrit. Since newborn screening
uses a predefined punch size to analyze samples (either 3.0 mm or 6.0 mm) the actual volume
will vary depending on hematocrit. It has been previously shown that samples with abnormally
low or high hematocrit have dramatic differences in sample volume which could result in the
misidentification of disorders (Mei et al., 2001).
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A major drawback to flow injection analysis is the lack of separation of isobars;
compounds having the same mass but are structurally different. In some cases the different
isobars are diagnostic for separate disorders, and clinical diagnosis is required for proper
identification of a disorder (Bennett, 2009; Sweetman, 2001). Leucine, isoleucine, and
hydroxyproline all have the same molecular ion 131 m/z and appear as a single entity in
newborn screening tests. Although leucine and isoleucine are both used as indicators for maple
syrup urine disease (MSUD) their response factors are different and elevated levels of one
isomer can influence the screening result (Chace et al., 1995). In addition, a variation in
hydroxyproline levels can lead to inaccurate diagnosis of MSUD (Matern, Tortorelli, Oglesbee,
Gavrilov, & Rinaldo, 2007). There are also several acylcarntines that have the same mass, C4isomers butyrylcarnitine and isobutrylcarnitine are symptomatic of two different disorders;
short-chain acyl-CoA dehydrogenase (SCAD) and isobutryrl-CoA dehydrogenase deficiency
respectively (Chace et al., 2003). C5-isomers valerylcarnitine and isovalerylcarnitine appear at
245 m/z and other species such as 3-hydroxyisovaleryl carnitine, 2-methyl-3-hydroxybutyryl
carnitine and butyrylcarnitine dicarboxylic acid (C4DC) appear at 262 m/z. These species are
indicators of specific disorders, but are not separated using flow injection analysis and require
additional testing for confirmation of the disorder. All final diagnostic tests for analysis of
amino acids and acylcarnitines involve some form of chromatographic separation.
Another issue not previously evaluated in newborn screening is the potential for the
matrix to affect the quantification of analytes. Although labeled internal standards are used for
quantification, the response of the internal standard could be affected differently relative to
the analyte by other compounds in the matrix (Trufelli et al., 2011). In addition there is the
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potential for matrix related components, such as phospholipids, to dramatically reduce the
ionization of some analytes to an undetectable level. Since there is no chromatographic
separation employed in the screening method, all the analytes appear at the same time as the
other matrix components. Matrix effects can dramatically affect quantification of analytes even
if labeled internal standards are used and should be evaluated in newborn screening methods
(Lindegardh, Annerberg, White, & Day, 2008). The FDA requires bioanalytical methods to be
evaluated for matrix effects to ensure that quantification is accurate and precise (US FDA.
Guidance for Industry: Bioanalytical Method Validation, 2001).
1.1.5 Misdiagnosis of patients
Established ranges have been determined for each analyte in order to differentiate
between normal healthy levels and diseased levels. Due to overlap in these ranges, cut-off
values have to be set. However, it has been reported that as many as 20% of babies initially
identified as having a disorder are later determined to be healthy (Sahai & Marsden, 2009).
Although, adjusting the cut-off values higher would reduce the number of false positives it
would also increase the occurrence of false negatives (Sweetman, 2001).
False positive cases occur when newborns are identified as having a disorder, but after
additional testing the child is determined to be healthy. This has less of an impact to the child,
but it has shown to result in psychological and emotional issues for the parents (la Marca et al.,
2007; Schulze et al., 2003; Sweetman, 2001). It has been reported that less than 27% of
newborns identified by current screening methods as having methylmalonic acidaemias are
diagnosed with this disorder after employing a more selective second-tier test (Matern et al.,
2007). Propionylcarnitine (C3) is the primary marker for methylmalonic acidaemias, however
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methylmalonic acid has been identified as a more selective marker. This example demonstrates
the poor specificity of current markers for some diseases that could be addressed by adding
more specific markers to the screening method. Proper diagnosis of MSUD using newborn
screening methods also has a high false positive rate due to lack of chromatographic separation
between leucine, isoleucine and hydroxyl proline, as discussed earlier. Most laboratories have
implemented second-tier testing for confirmation of disorders that have a high false positive
rate. These second-tier tests often involve a second analysis for more specific markers and
require a chromatographic separation.
1.1.6 Requirement for second-tier testing
As discussed above, one of the major issues with the current newborn screening
method is it is not completely diagnostic, and markers are not always specific to a single
disorder (Matern et al., 2007; Sweetman, 2001). Newborn screening laboratories have
implemented more selective second-tier tests for some disorders to confirm test positive
samples prior to physician notification (Matern et al., 2007). Although these second-tier tests
do provide additional specificity, additional instrumentation and personnel are needed for
these analysis. Some laboratories screen for more specific markers such as succinylacetone for
diagnosis of Tyrosinemia Type 1 (Al-Dirbashi et al., 2008; Matern et al., 2007; Turgeon et al.,
2008). Several second-tier tests have been published for the diagnosis of elevated C3 which is
a marker for four potential disorders: methylmalonic academia, cobalamin deficiency,
homocystinuria and propionic academia (la Marca et al., 2007; Magera, Helgeson, Matern, &
Rinaldo, 2000; Matern et al., 2007; Weisfeld-Adams et al., 2009). The current approach to
second-tier testing is that one second-tier test is employed for each disorder which results in
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multiple second-tier tests. Having a more comprehensive screening method would eliminate
the need for multiple second-tier tests, reducing costs and ensuring faster and more accurate
identification of certain disorders. To date there is not a comprehensive method that can
chromatographically separate both acylcarnitines and amino acids in a single analysis that
would be suitable for screening or as a second-tier test.
1.2 Chromatographic separation of acylcarnitines and amino acids
1.2.1 Current methods for acylcarnitines and amino acids
Analysis of acylcarnitines and amino acids can be very complex due to the nature of
these analytes. Amino acids are very polar compounds and are not well retained on
conventional reverse phase columns such as an octadecyl (C18) phase. This is due to the fact
that amino acids contain both an acidic and basic functional group and they are ionized under
most of the typical chromatographic conditions. This makes amino acids more water soluble
and therefore they stay in the mobile phase and do not interact with a hydrophobic stationary
phase. Acylcarnitines have extremely diverse polarity from carnitine being the most polar to
stearoylcarnitine (C18) which is very non-polar. The polarity differences between these
compounds are affected by the hydrophobic carbon chain attached to a portion of the
molecule. The length of this chain will affect the hydrophobicity of the molecule, resulting in
longer retention on a reverse phase column. Another issue with analysis of both amino acids
and acylcarnitines is that most of these analytes do not contain a chromophore necessary to
absorb UV light. Therefore, these analytes cannot be analyzed by UV or fluorescence
techniques without some type of derivatization to enhance their detection. Although there
have been several published methods for the analysis of amino acids and acylcarnitines, very
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few methods have included both in the same analysis. In addition, a rapid screening method
should be capable of chromatographically resolving all these analytes and isobaric species with
run time less than 5 minutes
Published methods for analysis of acylcarnitines employ a variety of chromatographic
conditions and modes of detection. As stated previously, analysis of acylcarnitines for UV
absorbance or fluorescence detection required some form of derivatization.
Pentafluorophenacyl trifluoromethanesulfonate (Minkler, Ingalls, & Hoppel, 2005) and 2-(2,3naphthalimino)ethyl trifluoromethanesulfonate (Minkler, Kerner, North, & Hoppel, 2005) have
been used for derivatization of acylcarnitines for UV and fluorescence detection respectively.
Although these methods are suitable for quantitative analysis of acylcarnitines the analysis
times are extremely long and they would not be practical for a rapid screening method or for a
second-tier test. An alternative approach would be to use electrospray ionization with mass
spectrometry detection. However, the current published methods are still not suitable for
newborn screening due to analysis times that are longer than 10 minutes (Ghoshal, Guo,
Soukhova, & Soldin, 2005; Maeda et al., 2007), the requirement for alternative instrumentation
(Chalcraft & Britz-McKibbin, 2009) or that they utilize ion pair reagents (Vernez, Wenk, &
Krahenbuhl, 2004). Comprehensive methods for analysis of acylcarnitines, such as dicarboxylic
acid and hydroxylated species have been reported, however quantification of all these species
adds additional complexity to the analysis and are not necessary for screening (Maeda et al.,
2008). Others have reported the separation of key isobars such as C4 and C5 which does allow
for differential diagnosis for short chain acyl-coenzyme A dehydrogenase deficiency (SCAD) and
isobutyryl-CoA dehydrogenase deficiency (IBCD) or isovaleric academia (IVA) (Forni, Fu, Palmer,
14

& Sweetman, 2010). Recently there was a report for the analysis of 48 acylcarnitines from dried
blood spots using UHPLC-MS/MS on a C18 column with a 15 minute analysis time (Gucciardi,
Pirillo, Di Gangi, Naturale, & Giordano, 2012). This method does provide chromatographic
separation for a comprehensive list of acylcarnitines including several isobars, but the analysis
time is still not practical for a rapid test. Table 1.1 provides a comparison of all the published
methods for acylcarnitine analysis.
Almost all the reported methods for amino acid analysis involve some form of
derivatization either pre-column or post-column. Derivatization is used to enhance the
retention of these analytes in reverse phase chromatography and to improve the detection by
UV absorbance or fluorescence. There are several commercial kits available for this analysis
including Agilent’s Aminoquant method and Water’s AccQ•Tag™ Ultra derivatization method
(Armenta et al., 2010). Although chromatographic separation for amino acids using these
methods can be achieved in approximately 10 minutes, both of these kits involve additional
derivatization reagents and specialty columns for the analysis. Kasper recently published a
review of current methods for the analysis of amino acids in biological samples by HPLC with UV
or fluorescence detection, ion-pair chromatography, capillary electrophoresis, GC/MS,
UPLC/MS and 2-dimensional NMR (Kaspar, Dettmer, Gronwald, & Oefner, 2009). A
comprehensive list of published methods for the chromatographic separation of amino acids is
included in Table 1.1. To date there are no published papers involving the separation of both
amino acids and acylcarnitines with a run time that would be comparable to the analysis time
to the newborn screening flow injection technique.
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Table 1.1: Comprehensive list of methods for used for analysis of acylcarnitine and amino acid
Compound
Class
Acylcarnitines

Analytes
15 acylcarnitines

Analysis
time
70 min

Instrumentation

Comments

Reference

HPLC-UV

Derivatization with
pentafluorophenacyl
trifluoromethanesulfonate

(Minkler et al.,
2005)
(Minkler, Kerner
et al., 2005)

16

7 long chain
acylcarnitines

13 min

HPLC-FLD

Derivatization with 2-(2,3naphthalimino)ethyl
trifluoromethanesulfonate

17 acylcarnitines

33 min

LC-MS/MS

Analysis of Human Serum and
Urine

(Maeda et al.,
2007)

17 acylcarnitines

33 min

LC-MS/MS

Analysis of Human Serum and
Urine

(Maeda et al.,
2008)
(Chalcraft & BritzMcKibbin, 2009)

7 acylcarnitines
and 13 amino
acids

16 min

CE-MS/MS

Requires alternative
instrumentation and only
analyzes for select
acylcarnitines

10 acylcarnitines

17 min

LC-MS/MS

Poor chromatography for
several of the acylcarnitines, no
derivatization required

(Ghoshal et al.,
2005)

LC-MS/MS

Previous method modified from
17 min to 10 minutes, no
derivatization required

(Ghoshal, Balay, &
Soldin, 2006)

10 acylcarnitines

48 acylcarnitines

10 min

15 min

UPLC-MS/MS

Most comprehensive method, but
it does not include quantitative
analysis of amino acids

(Gucciardi et al.,
2012)

Compound
Class
Acylcarnitines

Amino Acids

Analytes
6 long chain
acylcarnitines

25 amino acids

Analysis
time
12 min

10 min

Instrumentation
LC-MS/MS

60 min

17

Derivatization with ophthalaldehyde–2mercaptoethanol or
ophthalaldehyde
HPLC FLD

14 amino Acids

60 min

Derivatization with ophtalaldehyde, 2mercaptoethanol as
catalyst
HPLC-FLD

21 amino acids

30 min

Derivatization with ophtalaldehyde, 2mercaptoethanol as
catalyst

Reference

Method not comprehensive and (Jauregui et al.,
used for the analysis of PC-12
2007)
cells

UHPLC-FLD or LC/MS/MS Requires specialized reagents
and columns. Derivatization
Waters AccQ-Tag
with 6-aminoquinolyl-Nderivatization.
hydroxysuccinimidyl carbamate
HPLC Electrochemical
Detection

15 amino acids

Comments

(Armenta et al.,
2010)

Requires Derivatization,
specialized detection and long
analysis time

(Tcherkas,
Kartsova, &
Krasnova, 2001)

Not validated for biological
samples, requires derivatization
and long analysis time (glues)

(Peris-Vicente,
Gimeno
Adelantado,
Carbó, Castro, &
Reig, 2006)

Not validated for biological
samples, requires derivatization
(wine)

(Soufleros,
Bouloumpasi,
Tsarchopoulos, &
Biliaderis, 2003)

Compound
Class

Analytes

Analysis
time

Amino Acids

23 amino acids

17 min

38 amino acids

115 min

Instrumentation
HPLC FLD

15 min

Ion Exchange
LC-UV
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(Fekkes, 1996b)

Requires derivatization and
extremely long analysis time

(Le Boucher,
Charret, CoudrayLucas, Giboudeau,
& Cynober, 1997)

Ion pair chromatography

(de Person,
Chaimbault, &
Elfakir, 2008)

Ion pair chromatography

(Waterval,
Scheijen,
OrtmansPloemen, Habetsvan der Poel, &
Bierau, 2009)

Ion pair reagent:
nonafluoropentanoic
acid
Ion Pair UHPLC

30 min

Ionpair reagents:
Tridecafluoroheptanoic
acid

16 amino acids

60 min

HILIC LC/MS/MS

Monolithic Silica –FLD
10 min

Requires derivatization

Derivatization with
ninhydrin reagent

26 amino acids in
plasma and 22
amino acids in
urine

21 amino acids

Reference

OPA derivatization

Ion Pair LC/MS/MS
16 amino acids

Comments

Derivatization with with
4-fluoro-7-nitro-2,1,3benzoxadiazole (NBD-F)

Allows for separation of isomers (Langrock, Czihal,
but long analysis time
& Hoffmann,
2006)
Fast method monolithic column
but requires derivatization

(Song, Funatsu, &
Tsunoda, 2012)

Compound
Class

Analytes

Analysis
time

Instrumentation

Amino Acids

32 amino acids

25 min

CE-MS

20 amino acids

30 amino acids

5.5 min

30 min

Comments

Reference

No derivatization required but
long analysis time

(Soga, Kakazu,
Robert, Tomita, &
Nishioka, 2004)

UHPLC-UV&CD
Derivatization with 4fluoro-7-nitro-2,1,3benzoxadiazole
(NBD-F)

Fast analysis but not validated
for biological samples

(Eto, Yamaguchi,
Bounoshita,
Mizukoshi, &
Miyano, 2011)

GC/MS

Requires alternative
instrumentation and
derivatization

Derivatization with
propyl chloroformate

(food samples)

(Kaspar, Dettmer,
Gronwald, &
Oefner, 2008)
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1.2.2 Implementation of a high resolution chromatographic separation
There is a growing need to incorporate chromatographic separation into the current
newborn screening method for metabolism disorders (Bennett, 2009). The current newborn
screening method is acceptable for fast identification of certain metabolism disorders; however
there is not sufficient selectivity to accurately identify many of these disorders. Also, some of
the critical diagnostic markers are isobars which are not separated by flow injection analysis. In
addition, more specific markers are known for some of these metabolism disorders and have
been implemented in second-tier tests, but are not included in the newborn screening. By
adding a chromatographic separation to the current newborn screening method, separation of
isomers could be achieved and additional analytes could be added to the method. A
chromatographic separation would allow for differential diagnosis of several key metabolism
disorders. Butryrlcarnitine (C4) and isobutryrlcarnitine (ISO C4) are examples of unresolved
isomers which are diagnostic for separate disorders and can only be differentiated
chromatographically. Also not previously evaluated in newborn screening is the possibility that
the matrix suppresses the ionization of analytes, potentially affecting the quantification. In
flow injection analysis the analytes are eluted as a plug, such that there is no separation of
matrix components from the analytes. Since there is no separation, there is the potential for
analytes at higher concentrations to reduce the ionization of analytes at lower concentrations.
This competing ionization can result in poor sensitivity and could potential increase errors in
identification of a disorder. Employing a chromatographic separation could resolve matrix
components from the analytes, improving the sensitivity and improving the quantification of
the analytes.
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1.2.3 Theory and approach for chromatographic separation
Conventional high performance liquid chromatography has been unacceptable for
newborn screening due to long analysis times and the inability to separate all of these
compounds in a single analysis. Innovations in ultra-high pressure liquid chromatography
utilizing smaller particles and higher linear velocities, as shown by MacNair, Jorgenson and
coworkers has been able to obtain high efficiency separations in short analysis times (MacNair,
Lewis, & Jorgenson, 1997). The theoretical plate height, which is a measure of a column’s
efficiency, can be defined by the van Deemter Equation (Equation 1.3) (Miller, 2005).
Minimizing the theoretical plate height (H) ultimately improves the columns efficiency. Three
kinetic interactions play a role in the column efficiency; eddy diffusion (A), molecular diffusion
(B) and mass transfer (C). The B and C terms are both influenced by the linear velocity (u) of
the mobile phase. The optimal linear velocity (uopt) is dependent on particle size and diffusion
of the anaylte in the mobile phase (Dm) (Equation 1.4) (MacNair et al., 1997). Eddy diffusion (A)
is directly related to the particle size (dp) and packing efficiency (λ) of the column (Equation 1.5)
(Miller, 2005). Therefore, smaller particles reduce eddy diffusion and improve column
efficiency.
(Equation 1.3)
(Equation 1.4)
(Equation 1.5)
Using smaller particles at optimal conditions reduces the theoretical plate height, which
results in an increase the number of theoretical plates obtained per unit length of column. This
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allows shorter columns packed with smaller particles to achieve similar performance as longer
columns packed with larger particles. Ultimately this reduces analysis times without sacrificing
column efficiency.
Another critical aspect to our chromatographic separation is the stationary phase that
was selected. The stationary phase is critical to providing good chromatographic peak shape
and acceptable retention. There are several choices for stationary phases in liquid
chromatography from very polar silica (Si-OH) phases to very non-polar C18 bonded stationary
phases. Conventional reverse phase columns, such as C18 stationary phases, retain hydrophobic
analytes more than hydrophilic analytes. However, several of the amino acids and
acylcarnitines are extremely hydrophilic and they would not be well retained on a conventional
C18 column unless they were derivatized first. An alternative stationary phase, called
hydrophobic interaction chromatography or HILIC, employs a polar stationary phase and has
been used to separate compounds with diverse polarity (Hemström & Irgum, 2006). In
addition, the elution order is reversed when compared to separations on a C18 column,
hydrophilic solutes are more retained than hydrophobic.
The basic HILIC stationary phase consists of an unmodified silica particle with Si-OH as
the functional group, however there are also several bonded phases available (Hemström &
Irgum, 2006). The exact mechanism for retention of polar analytes is debated, although it is
thought that multiple types of interactions can occur including; adsorption, electrostatic and
dipole-dipole (Hemström & Irgum, 2006). Adsorption of analytes into and out of a water
solvated layer surrounding stationary phase particles appears to be a driving force for retention
(Hemström & Irgum, 2006). Therefore, hydrophilic analytes have a higher affinity for the water
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and will partition into this layer more readily, increasing their retention. Conversely,
hydrophobic analytes will have a higher affinity for the mobile phase and are less retained. The
overall result of this separation mechanism is longer retention for hydrophilic solutes than for
hydrophobic solutes. Modified silica bonded stationary phases provide alternative selectivity
for HILIC retention, include; diol, cyanopropyl, amide, anion exchange, cation exchange and βcyclodextrin (Hemström & Irgum, 2006). Hemström and Irgum have published a
comprehensive review of all the different HILIC bonded phases that are commercially available
(Hemström & Irgum, 2006). Several of these stationary phases provide unique selectivity for
acidic and basic compounds and while others are good for the separation of isomers. Although,
underivatized silica provides acceptable retention for polar solutes the amide bonded phase
shows improve peak shape for basic compounds and requires less time for re-equilibration
after gradient separation using buffers (Hemström & Irgum, 2006). A major advantage to HILIC
chromatography is the mobile phase is rich in organic solvent, which provides better
desolvation, ultimately improving sensitivity for electrospray ionization (ESI). Overall, HILIC
chromatography provides a unique selectivity that is ideal for separation of for both
acylcarnitines and amino acids.
The use of silica-bonded cyclodextrin as a secondary separation mechanism further
enhances the selectivity of this chromatographic system allowing for the separation of critical
isobars. Cyclodextrins have been used to separate enantiomers, diasteriomers and structural
isomers in multiple applications including CE, GC and HPLC (Ward & Baker, 2008). The
cyclodextrin ring is made up of multiple glucopyranosides attached together forming different
size rings; α (alpha) - six member ring, β (beta) – seven member ring and γ (gamma) an eight
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member ring (Tang & Ng, 2008). The size of the ring is important to the enhancing the
selectivity of this separation. If compounds are too big to fit inside the cyclodextrin ring then
there will not be any differences in retention of two isobars. Also if both of the molecules easily
fit into the cyclodextrin then the cyclodextrin will not provide added selectivity either. The
ideal case is when one of the two isomers will fit into the cyclodextrin and the other does not fit
as well, due to steric hindrance or repulsive interactions with the surface of the cyclodextrin.
There are various types of interactions that can occur between the cyclodextrin and the analyte
molecule, including van der Waals, hydrophobic, electro static and hydrogen bonding (Li &
McGuffin, 2007). The interior of the cyclodextrin ring is hydrophobic, allowing for better
retention of non-polar compounds; however the top of the cyclodextrin ring is more hydrophilic
due to hydroxyl groups, allowing for better retention of compounds that can hydrogen bond
with these hydroxyl groups. Therefore the retention is related to its size and structure of the
molecule, and is affected by its orientation and interaction with the cyclodextrin (Singh, Bharti,
Madan, & Hiremath, 2010; Li & McGuffin, 2007). This makes cyclodextrin an ideal phase for
separating structural isomers, since one isomer will be generally more retained than the other.
We combined both of these separation mechanisms to develop a rapid high resolution
chromatographic separation for the analysis of acylcarnitines and amino acids. The
chromatographic separation can be conducted in approximately the same time as the current
flow injection analysis. In addition, we were able to chromatographically separate key isobars
that are diagnostic markers for different metabolism disorders, improving the selectivity of the
analysis.
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1.3 Automated dried blood spot analysis
1.3.1 Recent advancements in automation for dried blood spot analysis.
Dried blood spot analysis has been extremely advantageous to newborn screening
allowing for samples to be easily collected, shipped and stored. However, the analysis of dried
blood spots involves more complexities due to multiple processing steps that are typically done
manually or with limited automation. This slows down sample processing and adds to the
workload of newborn screening laboratories. Another disadvantage of dried blood spot
analysis is a 3 mm punch has to be removed from the card for the analysis. Once this spot is
removed there is no way to directly track the sample back to the original card from which it was
taken. This lack of connection makes it difficult to ensure there are no samples that are mixed
up due to processing errors. Therefore, in order to improve the efficiency of dried blood spot
analysis and to minimize the potential for processing errors, we investigated the ability to
directly analyze newborn screening cards without the need to punch disks from the card.
Others have also investigated the direct analysis of dried blood spots using similar
approaches, however their research has been aimed at improving the efficiencies of dried
blood spot analysis for use in clinical trials in pharmacokinetic studies to support new drug
development (Barfield, Spooner, Lad, Parry, & Fowles, 2008; Beaudette & Bateman, 2004; Li &
Tse, 2010; Spooner, Lad, & Barfield, 2009; Uyeda et al., 2011; Youhnovski et al., 2010) and for
therapeutic drug monitoring (Edelbroek, Heijden, & Stolk, 2009). This work has been a driving
force in developing automated techniques so that hundreds of samples can be analyzed rapidly
with little to no operator intervention. Table 1.2 is a comprehensive list of articles published
for the direct analysis of dried blood spots. There are two primary designs that have been used
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for direct analysis of dried blood spots; flow through and direct surface sampling. The first
device developed in 2009 required a disk to be punched from the dried blood spot and placed
in a cartridge (Déglon, Thomas, Cataldo, Mangin, & Staub, 2009). The cartridge was inserted inline with the mobile phase and the analytes were eluted off the DBS. Although this approach
was successful it was extremely labor intensive and time consuming, since every sample had to
be individually processed. This design was later automated in 2011 using multiple clamping
devices to hold dried blood spots so that many samples could be analyzed, greatly improving
the efficiency (Déglon et al., 2011). An alternative approach was developed which involved
direct sampling of the surface of the dried blood spot using a device similar to a TLC plate
analyzer (Van Berkel & Kertesz, 2009). There are several advantages to this device; samples can
be processed without removing a punch, variable sample size can be analyzed and it could be
incorporated with in-line sample clean-up prior to analysis. The TLC sampling device was
pressed on the top of a dried blood spot and the mobile phase was used to elute the analytes.
This device has been recently automated with robotic instrumentation improving sample
through-put efficiency.
Other techniques that have been published for the direct analysis of dried blood spots
but they are not fully quantitative. The first technique involves analysis using ionization by
paper spray. A small triangle of paper is placed in a clamp inside the ion source of the mass
spectrometer. Mobile phase is pumped to the paper and a voltage is applied to the clamp
allowing for ionization of the analytes. The analytes are eluted off the paper and are ionized
and analyzed by mass spectrometry. The second technique involves the use of direct electro
spray ionization (DESI). DESI employs an electrospray source that is directed at the sample’s
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surface. A solvent is pumped through the source which is ionized. The charge from the solvent
is transferred to the surface and analytes are ionized and pulled into the mass spectrometer.
Both of these methods are direct ionization techniques in which the sample is directly analyzed
just prior to the mass spectrometer. Paper spray does allow for some separation depending on
the properties of the paper used, however DESI is a direct analysis without any
chromatographic separation. Although both of these techniques do allow for direct sampling of
dried blood spots, neither of these techniques would be a dramatic improvement over the
newborn screening method since they are only semi-quantitative techniques.
Both the TLC interface and flow through device have been employed for the
quantitative analysis of pharmaceutical compounds to support clinical pharmacokinetic studies
(Déglon et al., 2011; Heinig et al., 2011). These devices allow for quick analysis of DBS, and
have been fully automated to reduce sample handling requirements, improving sample tracking
with minimum off-line sample preparation. However, there are still some concerns with direct
analysis of dried blood spots including incorporation of an internal standard, dilution of out of
range samples and correction for hematocrit-induced variations in sample volume.
There have been multiple techniques used to add internal standard for on-line dried
blood spot analysis. The internal standard can be added to the sample prior to analysis either
into the blood prior to spotting it on filter paper (Abu-Rabie & Spooner, 2009) or after the blood
has dried (Déglon et al., 2009; Déglon et al., 2011). Although both of these techniques appear
to be acceptable they require additional sample handling that has to be done at the time of
sample collection or sufficiently before sample analysis. Adding internal standard to the blood
prior to spotting requires a larger volume of sample to be drawn, measured accurately before
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adding the internal standard. This approach is not practical for newborn screening which is
very simplistic and would add more complexity to the sample collection. A recent technique
was developed by Abu-Rabie et. al. uses a piezo electric spray device to add internal standard
to the dried blood spot prior to analysis and allowing it to dry (Abu-Rabie et al., 2011). An even
coating of internal standard is sprayed across the surface of the dried blood spot and allows for
the internal standard to bind to the matrix and paper components similarly to the analyte.
Once the samples are dried the DBS is analyzed by a flow injection technique so that the
internal standard elutes with the analytes. This approach was acceptable for the analysis of
acetominophen and sitamaquine using direct analysis with the TLC interface. Although adding
the internal standard to the DBS prior to analysis appears to an acceptable technique, it adds
additional sample handling requirements and delays time to analysis. An alternative approach
would be to load a plug of internal standard into a loop and inject it through the DBS as the
analytes are eluted (Heinig, Wirz, Bucheli, & Gajate-Perez, 2011). This technique appears to be
the best solution since it minimizes sample processing steps and can be easily integrated into
most analytical systems.
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Table 1.2: Current approaches used for direct analysis of dried blood spots
Technique

Internal Standard
Approach

Flow through

Added to DBS
prior to analysis

Saquinavir, Imipramine, Verapamil

First Publication of on-line (Déglon et al., 2009)
desorption of dried blood
spots

Added to DBS
prior to analysis

Flurbiprofen and its metabolite 4hydroxyflurbiprofen

Method was fully
(Déglon et al., 2011)
validated and used for the
evaluation of a
pharmacokinetic study

Internal Standard
added to blood
before spotting

Acetaminophen, Sitamaquine,
Propranolol

First publication of TLC
interface for dried blood
spot analysis. No
chromatographic
separation

(Van Berkel & Kertesz,
2009)

Internal Standard
added to blood
before spotting

Acetaminophen, SB243213,
Sitamaquine, Ibuprofen, 4Nitrophthalic acid Proguanil,
Simvastatin, Benzethonium chloride

Optimization of elution
conditions

(Abu-Rabie & Spooner,
2009)

Evaluated internal
standard addition
to paper before
and after spotting
blood and on-line
using loop
injection

Not given, pharmaceutical compound

Incorporated column
switching and on-line SPE
cleanup

(Heinig, Wirz, & GajatePerez, 2010)

TLC

Analysis

Comments

Reference
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Technique

Internal Standard
Approach

TLC

Internal Standard
added to blood
before spotting
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Paper Spray

Paper Spray

Analysis

Comments

Reference

Acetominophen and Sitamaquine

Evaluated the robustness
for direct analysis of DBS
and dried plasma samples
(DPS)

(Abu-Rabie & Spooner,
2011)

IS sprayed onto
dried blood spot
prior to analysis

Acetominophen and Sitamaquine

Evaluated the use of
(Abu-Rabie et al., 2011)
spraying IS onto DBS prior
to analysis. Samples were
processed manually and
with TLC interface

Internal standard
added by loop
injection on-line

Oseltamivir (Tamiflu®) and
Oseltamivir carboxylate

Evaluated a new device
that directly desorbs
sample on-line with
chromatographic
separation

(Heinig et al., 2011)

Internal Standard
added to blood
before spotting

Amitriptyline and Sitamaquine

Analysis of therapeutic
Drugs in DBS

(Manicke, Abu-Rabie,
Spooner, Ouyang, &
Cooks, 2011)

Added to DBS just
prior to analysis

Propranolol and Atenolol

Evaluated the potential to ( Manicke et al., 2011)
analyze drugs in DBS
using paper spray

No Internal
Standard

Lidocaine, Amitriptyline,
Sunitinib, Verapamil,
Citalopram

Analysis of therapeutic
drugs in DBS using silica
coated paper substrate

(Zhang, Xu, Manicke,
Cooks, & Ouyang,
2012)

Technique

DESI
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Micro
Extraction

Internal Standard
Approach

Analysis

Comments

Reference
(Yang et al., 2012)

Internal Standard
added to blood
before spotting

Analysis of Acylcarnitines

Similar to flow injection
analysis, no
chromatography shown

Internal Standard
was added to the
blood prior to
spotting

Prazosin, Sitamaquine, Terfenadine
and Verapamil

DBS were directly
(Wiseman, Evans,
analyzed using desorption Bowen, & Kennedy,
electrospray ionization
2010)

Internal Standard
added to blood
before spotting

Verapamil, Sitamaquine, propranolol
sulforaphane, sulforaphane N-acetyl
cysteine (NAC) conjugate,
sulforaphane glutathione (G)
conjugate

No Chromatographic
separation, analysis is
only semi quantitative
Liquid micro extraction of
DBS using Advion
NanoMate chip-based
infusion
Directly extracts analytes
off the surface of the
sample and infuses them
into the mass
spectrometer

(Kertesz & Van Berkel,
2010)

1.3.2 Advantages of direct DBS analysis for newborn screening
Newborn screening is a labor intensive process requiring samples to be processed by
multiple methods. In addition, the typical work load for a newborn screening laboratory ranges
from 350 to 1500 samples per day (Chace, 2009). Multiple technicians and experienced
chemists are required to process and analyze all these samples and results need to be reported
as soon as possible so that treatment can be started for affected children. Overall, this is an
ideal environment to employ automated techniques, to improve laboratory efficiency and
reduce operating costs (Hamilton, 2007). Implementation of direct analysis of dried blood
spots could provide a dramatic benefit to newborn screening. Also sample tracking and data
analysis could be directly linked using automation devices such as bar code readers, reducing
sample processing errors.
1.3.3 Development of an in-line desorption device for dried blood spot analysis
In order to address the needs of newborn screening, we have developed an in-line
desorption device for direct measurement of the dried blood spot without the need punching
disks from the filter paper cards eliminating off-line sample processing. This device will
minimize human intervention and reduce misidentification of samples due to processing errors.
Our approach involves clamping a dried blood spot between two in-line filters which provides a
leak free seal. We tested the sealing properties for our device under various conditions to
ensure the integrity of the sample was not compromised. The elution parameters were
optimized to determine the most effective solvent composition and flow rate to quickly and
efficiently elute the analytes. Finally the device was incorporated with chromatographic
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separation using an Acquity UPLC HILIC Amide column to separate leucine, isoleucine and
hydroxyproline, which are commonly analyzed in second-tier testing for MSUD.
1.4 Factors affecting sample volume in dried blood spot analysis
1.4.1 Evaluation of hematocrit in dried blood spots
Another critical issue in dried blood spot analysis is defining the sample volume from an
excised spot. It is well known that sample volume for dried blood spots is dependent on the
patient’s hematocrit (Mei, Alexander, Adam, & Hannon, 2001). Hematocrit is defined as the
density of red blood cell per unit volume of blood. Samples with a high hematocrit will have
more red blood cells than samples with a low hematocrit. This is important because the
hematocrit affects the viscosity of the blood which in turn will affect the diffusion properties of
blood on the filter paper. Newborn screening cards are tested to ensure that blood with a
specified hematocrit will diffuse consistently to reduce lot to lot variability (Mei et al., 2001).
However, samples with a high hematocrit do not diffuse as far as samples with a low
hematocrit. It has been shown that the plasma volume can vary by as much as 47% from a
sample with low hematocrit to a sample with high hematocrit (Mei et al., 2001). Table 1.3 is a
comprehensive list of publications related to the effect of hematocrit on dried blood spot
analysis.
In order to correct for differences in hematocrit Li et. al. have suggested spotting a
known volume of blood on perforated filter paper and analyzing the entire spot (Li, Zulkoski,
Fast, & Michael, 2011). Although this has been shown to work for analysis of pharmaceutical
compounds in blood for pharmacokinetic studies this technique is not ideal for newborn
screening. Newborn screening relies on a simplistic sample collection approach where the
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newborns heal is pricked with a lance and the blood is spotted on the filter paper by dabbing
the paper on the newborn’s heal. Spotting an exact amount of blood would require health care
providers to draw blood from the child, collect the sample in a tube and then pipet a specified
volume on the card. Although this would alleviate the concern related to sample volume it
would introduce additional complexities to the current sample collection procedure and could
cause errors related to inaccuracies in pipetting.
If the hematocrit of the blood could be determined at the time of sample collection then
it could be used to estimate sample volume at the time of analysis. Although this could be
done by the health care providers at the time of sample collection it would increase the work
load and requires additional instrumentation for the analysis. An alternative approach would
be to determine the hematocrit of the dried blood spot at the time of sample analysis. This has
been previously attempted using the newborn screening test for hemoglobinopathies (Orsini,
Yeman, Bodamer, Mühl, & Caggana, 2010). This test is a semi-qualitative method for the
analysis of hemoglobinvariants F, A, S, D, C, and E. Samples are analyzed by HPLC UV at 415nm
and the peak areas of the different hemoglobin forms are summed together to get total
hemoglobin. The data was then used to relate hemoglobin content to hematocrit (Orsini et al.,
2010). Although there was a good correlation between hemoglobin and hematocrit the
acceptability of the method was questionable. They reported an overall percent accuracy of
108% with a range of 73.5–142%. Although there does appear to be some issues with the
accuracy, this method shows feasibility to determine hematocrit in dried blood spot samples.
Once the hematocrit level is determined it can be used to estimate sample volume from a
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predetermined punch size, eliminating the need to pipette specified volumes on the filter
paper.
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Table 1.3: Reported issues related to hematocrit effect on sample volume in dried blood spot analysis
Analytes
Acetaminophen and
sitamaquine

Investigation
Evaluate the effect of
hematocrit on assay bias when
using DBS samples for the
quantitative bioanalysis of
drugs

Comments
Showed little bias in sample
volume within normal range,
however only 15 µL of blood was
spotted on cards. Only two
analytes investigated

Reference
(Denniff & Spooner,
2010)

Showed that analyte
concentrations were significantly
different between 75 µL and 100
µL blood was spotted on cards
Approximately a 50% difference
in sample volume between 30%
and 70% hematocrit. Only a 13%
difference in sample volume was
observed for peripheral punch
and center punch
Combined effect of
approximately 30% was observed
for phenylalanine concentrations

(O'Broin, 1993)

I-L-Thyroxine

Evaluated the influence of
hematocrit and sample volume
added to filter paper

125

I-L-Thyroxine

Evaluated hematocrit effects
on sample volume and
potential chromatographic
effects.

36

125

Phenylalanine

Evaluated the combined
effects of hematocrit, loading
blood volume and filter paper
source.

(Mei et al., 2001)

(Adam et al., 2000)

Investigation
Evaluate the effect of
hematocrit and punch location
for DBS analysis

Cyclosporin A

Evaluated hematocrit effects in
DBS samples

Compounds with diverse
lipidpholicity

Evaluated the effects of
hematocrit and punch location
on assay bias with a variety of
filter papers.

Unknown compound

Evaluated the effect of sample
volume on blood spot
diameter on DMPK-B and
DMPK-C filter paper cards.
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Analytes
Amino acids and acylcarnitines

Comments
Dramatic differences in analyte
concentrations were observed
for low and high hematocrit
samples. Some analyte
concentrations in peripheral
punches were significantly
different than for center punches
No significant differences from
30% to 56% hematocrit were
observed for a 50 µL spot and a
8 mm punch
Significant differences were
observed for different hematocrit
levels and for center versus
peripheral punch locations

Reference
(Holub et al., 2006)

The diffusion properties of the
two papers were dramatically
different. The DMPK-C paper
diffused much more evenly.
Analyte concentration increased
up to about 50 µL of blood then
leveled off.

(Fan et al., 2011)

(Wilhelm, den Burger,
Vos, Chahbouni, &
Sinjewel, 2009)
(O'Mara, HudsonCurtis,
Olson,Yueh,Dunn,Spoo
ner, 2011)

1.4.2 Background and theory of diffuse reflectance
There are several published papers that have been reported using reflectance as a tool
to analyze properties of blood and blood components in vitro and in vivo for decades (Johns,
Giller, & Liu, 2001; Meinke, Gersonde, Friebel, Helfmann, & Müller, 2005; Schmitt, Meindl, &
Mihm, 1986; Serebrennikova, Smith, Huffman, Leparc, & García-Rubio, 2008; Steinke &
Shepherd, 1986; Steinke & Shepherd, 1988; Steinke & Shepherd, 1988; S. Zhang, Soller, Kaur,
Perras, & Salm, 2000; Zijlstra, Buursma, & Meeuwsen-van der Roest, 1991; Zonios & Dimou,
2006). The main advantage to reflectance is that it is a non-destructive technique and can be
used to directly analyze samples without the need for any preprocessing. Although there have
been several reported papers that evaluate hematocrit in vivo and in vitro using reflectance
these methods are only applicable to red blood cells in solution. An alternative approach
would be required to determine the hematocrit in dried blood spot analysis. Dried blood spot
analysis is more closely related to the analysis of surfaces which are commonly analyzed using
diffuse reflectance techniques.
Diffuse reflectance has been used to analyze solid samples including; paint, soil, paper,
coal food and biological samples (Subhash et al., 2006; Ulery, Drees, & Soil Science Society of
America, 2008; Wesley & Wendlandt, 1966; Yu et al., 2008). The principle of diffuse reflectance
is used to explain multiple interactions that reflected light has with a mat or rough surface
(Ulery et al., 2008; Wesley & Wendlandt, 1966). When light is directed at a rough surface the
light is variously reflected, scattered, refracted and absorbed. In order to better understand
diffuse reflectance one must first understand the basics of specular reflectance. In the most
simplistic case, when light is reflected from a smooth surface it can be defined by the Fresnel
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equation, Equation 1.6, where the reflected light (R) is dependent on the incident radiant
energy (Io) and the intensity of the light reflected (I).

(Equation 1.6)

The radiant energy of the incident light and reflected light is dependent on the refractive index
(n) of the medium and the absorption index (k) (Wesley & Wendlandt, 1966). The angle (θ1) of
the incident light from a normal perpendicular to the surface will be the same as the reflected
angle (θ2) (Figure 1.5). The intensity of the light reflected from the surface will be dependent
on the amount of light absorbed by the sample (k) and the amount of light that penetrates the
sample (n2). Reflectance of smooth surfaces such as these are commonly performed to
determine the absorption properties or refractive index of a material. However, the surface
must be smooth and the crystalline structure of the material must not diffuse light.

θ1

θ2
n1
n2
Diffuse Reflectance

Specular Reflectance

Figure 1.4: Diagram to show the difference between how light is reflected by specular
reflectance and diffuse reflectance
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Diffuse reflectance is more complex then spectral reflectance and no theories are
completely valid for all cases (Wesley & Wendlandt, 1966). In diffuse reflectance light is
scattered in multiple directions depending on the crystal structure of the material and/or the
roughness of the surface (Figure 1.4). For a non-absorbing surface where the radiation is
scattered homogeneously in all directions, the Lambert Cosine Law can be used, Equation 1.7
(Wesley & Wendlandt, 1966),
Lambert Cosine Law:

(Equation 1.7)

where B is the intensity of the radiant light, α is the angle of the incident light and θ is the angle
of the reflected light. The Lambert Cosine Law was shown to be valid for non-absorbing
powders at certain angles, however at some angles the results were unacceptable (Wesley &
Wendlandt, 1966). Absorbing materials add additional complexity to developing theoretical
models, since some of the light is absorbed by the sample or penetrates into the sample
altering the properties of the reflected light.
Reflectance properties of blood and tissue samples have been extensively investigated.
One group investigated the reflectance properties of tissue samples indicated that the reflected
light was dependent on the size and density of cellular components (Yu et al., 2008). It has also
been reported that the optical absorbance of the red blood cells in vitro solutions affect the
intensity of light that is reflected and light scattering properties were related to hematocrit
(Lovell, Hebden, Goldstone, & Cope, 1999). Although these measurements were made in
different media from a dried blood spot, it does show the potential to measure the intrinsic
properties of blood using reflectance. Our approach is based on the phenomena that as the
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hematocrit increases the red blood cell density increases across the surface of the dried blood
spot and the surface will scatter and absorb light depending on the concentration of the cellular
components.
1.4.3 Diffuse reflectance of dried blood spots
In order to correct sample volume for differences in hematocrit on dried blood spots,
we have investigated the use of UV/NIR reflectance to relate hematocrit. By relating
hematocrit to a UV/NIR measurement we can then estimate sample volume from a predefined
punch size. We will test our approach with donor samples prepared at various hematocrit
levels and fortified at known concentrations with acylcarnitines C0, C2, C3, C4, C5, C6, C8, C10,
C12, C14, C16 and C18. Correcting for sample volume should improve the accuracy of newborn
screening potentially improving the positive predictive value and will reducing errors associated
with not correcting sample volume for high and low hematocrit levels.
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CHAPTER 2

A QUANTITATIVE METHOD FOR ACYLCARNITINES AND AMINO ACIDS
USING HIGH RESOLUTION CHROMATOGRAPHY AND TANDEM MASS
SPECTROMETRY IN NEWBORN SCREENING DRIED BLOOD SPOT
ANALYSIS
Drawn from manuscript published in Journal of Chromatography B, 903(2012) 142-149.

2.1. Introduction
Newborn screening is claimed to be “one of the most successful public health programs”
(Sahai & Marsden,2009) ever initiated and originated with Robert Guthrie screening for
phenylketonuria (PKU) (Guthrie & Susi, 1963). Since its inception, additional markers have been
identified for different disorders and added to the panel of screening tests. However, most of
these methods required a separate analysis for each disorder. It wasn’t until a method was
developed by researchers at Duke University that multiple heritable metabolic disorders could
be identified in a single test (Millington et al., 1990). This approach relied on a technique
called flow injection in which samples were directly injected onto the mass spectrometer
without chromatographic separation. Mass spectra were extracted from the data allowing for
identification of metabolic disorders based on elevated levels of specific acylcarnitines. Over
the years additional analytes were added to this screening method allowing for early detection
of more than 20 different metabolism disorders in a single analysis (Chace et al., 2003;
42

Sweetman, 2001). Although this approach has proven to be successful and provides a rapid
screening test for many disorders, the analysis is not fully quantitative (Sahai & Marsden, 2009),
and screen positive results often need to be confirmed by a second-tier test (Lehotay et al.,
2011).
One major disadvantage with this flow injection approach is its inability to differentiate
isobaric species associated with different metabolic disorders resulting in additional testing to
identify the specific disorder (Bennett, 2009; Matern et al., 2007; Sahai & Marsden, 2009;
Sweetman, 2001). Chromatographic separation is required to separate these isobars, however
current approaches involve lengthy analysis times (Maeda et al., 2007), use ion pair reagents
(Piraud et al., 2005) or require additional instrumentation such as capillary electrophoresis
(Chalcraft & Britz-McKibbin, 2009). Another potential problem for a flow injection approach is
quantification using a single point response factor with stable isotope labeled internal
standards. Assuming that the responses of the isotopically labeled internal standards are
equivalent to their corresponding analyte can lead to inaccuracies in quantification and
fluctuations in quantification limits. It has been reported, that the response factors of the
analytes and internal standards must be evaluated to accurately quantify analytes (De Jesús,
Chace, Lim, Mei, & Hannon, 2010). Chace and coworkers have reported the quantification of
leucine can be impacted by unresolved isobaric species that have different response factors
(Chace et al., 1995). Although this research allowed for the identification of MSUD, it also
shows that response factors can be affected by unresolved isobars. Not previously discussed
regarding newborn screening, is the potential for response factors to be affected by matrix
effects. Although, stable isotope labeled internal standards reduce errors associated with
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matrix suppression there are reports that show analyte to internal standard response ratios can
be affected (Jemal, Schuster, & Whigan, 2003; Lindegardh et al., 2008; Trufelli, Palma, Famiglini,
& Cappiello, 2011). In addition, since there is no chromatographic separation employed in the
flow injection screening method, ionization can be reduced by the presence of matrix related
components or by other analytes at higher concentrations (Trufelli et al., 2011). This could
result in the misidentification of samples close to the cut-off value, if the matrix suppression
reduces or enhances the ionization of an analyte differently than its corresponding internal
standard.
The original and still widely used approach for flow injection analysis involves
derivatization of acylcarnitines and amino acids with n-butanol and HCl to form butyl esters
which enhances the sensitivity of certain analytes (Chace et al., 2003). However, the caustic
nature of this derivatization is a safety hazard to laboratory personnel and hydrochloric acid is
corrosive to laboratory equipment. More recently a method has been developed without
derivatization, but this approach may result in lower intensity for specific dicarboxylic acid
acylcarnitines (De Jesús et al., 2010). Although both of these techniques have been shown to
provide acceptable results for screening purposes there is still the potential for a high false
positive rate for some disorders (Matern et al., 2007; Sahai & Marsden, 2009). This has
resulted in the need for implementation of second-tier tests to identify certain disorders
(Matern et al., 2007; Sahai & Marsden, 2009). The current approach to confirm specific
disorders is one second-tier test for each disorder, resulting in multiple second-tier tests that
have to be used by newborn screening laboratories and/or physicians. To date there is not a
comprehensive second-tier test able to quantify acylcarnitines and amino acids in a single
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analysis. Common practice for quantitative analysis of acylcarnitines and amino acids profiles
requires a second blood sample to be drawn from the infant and sent to a clinical laboratory for
analysis. This can result in unnecessary parental anxiety for false positive cases and further
delaying the time to diagnosis. Therefore, there is a need for a rapid second-tier test that could
be used to improve identification of the confounding disorders associated with results obtained
by flow injection newborn screening methods.
Typical methods employed by clinical laboratories for quantitative analysis of
acylcarnitines and amino acids are not usually available within public health newborn screening
laboratories. In addition, these methods are not commonly performed together, so samples
are analyzed by separate procedures using different instruments. The reported methods for
acylcarnitines are not practical for second-tier testing due to long analysis times (Maeda et al.,
2007; Maeda et al., 2008; Zuniga & Li, 2011), poor chromatography (Ghoshal et al., 2005), or
involve alternative instrumentation such as capillary electrophoresis (Chalcraft & BritzMcKibbin, 2009). There are many methods available for amino acid analysis; however, the
majority involves derivatization of samples followed by HPLC-UV, FLD, LC/MS or GC/MS (Kaspar
et al., 2009). These methods typically have analysis times longer than ten minutes and require
costly derivatization techniques to enhance sensitivity and retention. One published method
for the analysis of amino acids does not require derivatization; however the analysis time is 50
minutes (Langrock, Czihal, & Hoffmann, 2006), which would be unacceptable as a rapid secondtier test. Our method is the first comprehensive method capable of chromatographically
separating twelve acylcarnitines and seven amino acids in 2.2 minutes, with a total injection to
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injection cycle time of 3.1 minutes, a dramatic improvement over all other previously reported
techniques.
The combination of high resolution chromatography and the unique selectivity of HILIC
stationary phase are ideal for fast chromatographic separation of both amino acids and
acylcarnitines without the need for derivatization or ion pair reagents. It has been reported
that ultra-high pressure liquid chromatography using smaller particles and higher linear
velocities are able to achieve high efficiency separations in faster analysis times compared to
conventional HPLC separations (MacNair et al., 1997). In addition, polar stationary phases such
as hydrophilic interaction liquid chromatography (HILIC) are better suited to retain diverse
polarity analytes and offer improved sensitivity over reverse phase chromatography (Hemström
& Irgum, 2006). The basic HILIC stationary phase consists of an unmodified silica particle with
Si-OH as the functional group, however there are also several modified silica phases that are
commercially available (Hemström & Irgum, 2006). Although the unmodified phase has been
widely used for HILIC chromatography the HILIC amide phase provides better peak shape for
basic analytes and takes less time to re-equilibrate between injections (Hemström & Irgum,
2006). Using both UHPLC and HILIC allowed us to developed a complementary rapid method
that could be used by newborn screening laboratories to identify fatty acid oxidation disorders,
amino acid metabolism disorders and organic acid disorders. In addition, the chromatographic
separation resolves leucine, isoleucine and hydroxyproline allowing for confirmation of MSUD,
which is not possible with the flow injection methods. This analysis is performed with the
same sample extract used in the non-derivatized screening method to rapidly confirm abnormal
screening results. In addition, quantification is based on a full calibration using reference
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standards prepared in whole blood and dried on newborn screening cards. Alternative
conditions were used to resolve butyrylcarnitine (C4) from isobutyrylcarnitine(ISO C4) along
with valerylcarnitne(C5) from isolvalerylcarninte (ISO C5) which would allow for differential
diagnosis for short chain acyl-coenzyme A dehydrogenase deficiency(SCAD) and isobutyryl-CoA
dehydrogenase deficiency(IBCD) or isovaleric academia (IVA). This methodology provides
newborn screening laboratories with a complementary rapid second-tier test which is able to
confirm multiple metabolism disorders in a single analysis.

2.2 Materials and methods
2.2.1 Materials and reagents
Acylcarnitine reference standards (purity > 95%) were purchased from VU Medical
Center Metabolic Laboratory, (Amsterdam, The Netherlands) and amino acid reference
standards (purity > 96%) were purchased from Sigma Aldrich (Milwaukee, WI, USA). Stable
isotope labeled amino acids and acylcarnitines reference materials (purity > 98%) were
obtained from Cambridge Isotopes (Andover, MA, USA). Hydroxyproline obtained from ARCOS
Organics (Morris Plains, NJ, USA) was used as a system check to confirm the retention time.
HPLC grade acetonitrile, formic acid and ammonium formate were from Fisher Scientific
(Pittsburgh, PA, USA). Control human sodium heparin whole blood was obtained from
Biochemed (Winchester, VA, USA). Newborn screening cards, 903 Protein Saver, were obtained
from Whatman (Piscataway, NJ, USA). A 22 Multiple Syringe Pump from Harvard Apparatus
(Holliston, MA, USA) and a 250 µL Hamilton gas tight syringe from Fisher Scientific (Pittsburgh,
PA, USA) was used for infusion tests.
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2.2.2 Chromatographic instrumentation
Chromatographic separations were conducted with a Waters Acquity HILIC Amide
column, 2.1 x 50 mm, 1.7 µm; Waters Corp. (Milford, MA, USA). Separation of C4 and C5
isomers was achieved by placing a Supelco Astec CYCLOBOND™ I 2000 Chiral HPLC guard
column, 1.0 x 20 mm, 5 µm from Sigma Aldrich (Milwaukee WI, USA) prior to the HILIC Amide
column. A Waters Acquity UPLC pump and sample manager were used for analysis and
gradient separation. A Waters Premier triple quadrupole mass spectrometer (Milford, MA,
USA) equipped with electrospray ionization (ESI) source in positive ion mode was used.
Optimization of the instrument parameters including desolvation temperature, source
temperature, desolvation gas flow, cone gas flow, capillary voltage, cone voltage and collision
energy was performed by direct infusion of a solution containing acylcarnitines, amino acids
and their labeled internal standards. Optimal sensitivity was achieved using 3.8 kV for the
capillary, 390 oC desolvation temperature with nitrogen as the desolvation gas at a flow of 800
L/hr. Cone gas was nitrogen at a flow of 20 L/hr with a source temperature of 110 oC. Argon
was used for the collision gas at a flow of 0.4 L/hr. Multiple reaction monitoring (MRM) was
used for all analytes and internal standards. Specific transitions were used for each compound
with optimized cone voltage and collision energy shown in Table 2.1. In order to monitor for all
these transitions, MRMs were scheduled based on the retention time of each analyte to
achieve a minimum 0.4 minute window around each peak with a 0.02 second dwell time and a
0.02 second inter-scan delay.
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Table 2.1: Acylcarnitines and amino acids analyzed and the mass spectral settings for MRM
mode
ID

CV
(V)

CE
(eV)

MRM
Transition

I.S.

I.S. MRM
Transition

Time segment
(min)

Carnitine

C0

22

20

161.9→84.6

C0-D9

170.9→84.6

1.73 to 2.03

Acetylcarnitine

C2

22

20

203.9→84.6

C2-D3

206.9→84.6

1.57 to 1.87

Propionylcarnitine

C3

22

20

217.9→84.6

C3-D3

220.9→84.6

1.43 to 1.73

Butyrylcarnitine

C4

22

21

231.9→84.6

C4-D3

235.0→84.6

1.31 to 1.61

Valerylcarnitine

C5

22

23

246.0→84.6

C5-D9

255.1→84.6

1.21 to 1.51

Hexanoylcarnitine

C6

22

23

260.0→84.6

C8-D3

291.1→84.6

1.10 to 1.40

Octanoylcarnitine

C8

22

23

288.1→84.6

C8-D3

291.1→84.6

0.97 to 1.27

Decanoylcarnitine

C10

22

28

316.1→84.6

C8-D3

291.1→84.6

0.80 to 1.10

Lauroylcarnitine

C12

22

28

344.1→84.6

C14-D9

381.2→84.6

0.63 to 1.01

Myristoylcarnitine

C14

22

28

372.1→84.6

C14-D9

381.2→84.6

0.63 to 1.01

Palmitoylcarnitine

C16

22

28

400.2→84.6

C16-D3

403.2→84.6

0.00 to 0.95

Stearoylcarnitine

C18

22

28

428.2→84.6

C16-D3

403.2→84.6

0.00 to 0.95

Phenylalanine

Phe

20

15

165.8→119.7

Phe-D6

171.8→125.7

1.37 to 1.67

Leu/Ile

18

11

131.8→85.7

Leu-D3

134.85→88.7

1.41 to 2.03

Methionine

Met

14

11

149.8→103.6

Met-D3

152.85→106.6

1.50 to 1.80

Tyrosine

Tyr

15

14

181.8→135.8

Tyr-D6

187.8→141.8

1.54 to 1.84

Valine

Val

20

8

117.8→71.8

Val-D8

125.8→79.7

1.60 to 1.90

Citrulline

Cit

16

10

175.8→158.7

Cit-D2

177.8→160.7

1.88 to 2.18

Analyte

Leucine/Isoleucine
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2.2.3 Preparation of dried blood spots
For the validation portion of this study, sodium heparinized human whole blood was
fortified at 6 levels for a calibration curve and at 4 additional levels for quality control samples.
Individually prepared reference standards containing acylcarnitines and amino acids were
spiked into whole blood to fortify samples at the desired concentration to prepare the highest
calibration standard and quality control sample. These samples were then serially diluted to
prepare the additional calibration levels and quality control samples. Each dried blood spot
was prepared by spotting 50 µL of sample onto a Whatman, 903 Protein Saver newborn
screening card. These samples were allowed to dry for at least 2 hours at room temperature
and then stored at 0-5 oC until analyzed.
2.3. Results and discussion
2.3.1 Response factor evaluation
In newborn screening, response factors are used to quantify analytes and set cut-off
values to help identify children at risk of having a metabolic disorder. The analyte concentration
is determined based on Equation 2.1 where the response factor is often not calculated and
assumed to be equal to one. However, this assumption can lead to errors in calculated
concentrations if the response factors deviate from one. We evaluated the response factors for
all analytes using both external solutions and extracted samples to determine if the sample
matrix had a significant effect on the response factors. The analyte response factors were
initially determined for each analyte by flow injection analysis without derivatization using
external standards containing both analytes and internal standards. External standards were
prepared such that the final concentrations of the analytes and internal standards were
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equivalent. Serial dilutions were made to achieve five-point response curves with
concentrations above and below target concentration of internal standard in the final extract.
For flow injection analysis, 3 replicate injections of an external standard containing analytes and
internal standards were injected onto the LC/MS/MS system and the response from 50 scans
were averaged, which is the maximum number of scans across the center of the elution plug.
The responses of each analyte and their respective isotopically labeled internal standard were
evaluated. Data for carnitine and acetylcarnitine were plotted to show the relationship
between response and concentration, Figures 2.1A and 2.1B respectively. Equation 2.2 was
used to calculate the response factors for each analyte and its isotopically labeled internal
standard at various concentrations. The response factors for all the analytes were plotted
versus concentration to evaluate if the response factors were consistent across the
concentration range. Example plots for response factors for carnitine and acetylcarnitine are
shown in Figures 2.2A and 2.2B respectively. The average response factors were calculated by
averaging the response factor across all concentrations and results are reported in Table 2.2.

Equation 2.1: Conventional calculation for concentration for analytes extracted from dried
blood spots

Equation 2.2: Response factor determined using the instrument response for an analyte and
internal standard analyzed at identical concentrations

51

Equation 2.3: Calculation of accuracy for the response factor determined using internal
calibration curve

Legend: Carnitine (squares) and carnitine-D9 (diamonds) for external standards using flow
injection analysis. Each sample analyzed in triplicate, error bars represent 1 S.D..
Figure 2.1A: Plot of external standard response (n =3) versus concentrations for carnitine and
carnitine-D9, samples analyzed by LC/MS flow injection analysis with precursor ion scan
mode for the production of 85 m/z
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Legend: Acetylcarnitine (squares) and acetylcarnitine-D3 (diamonds) for external samples using
flow injection analysis. Each sample analyzed in triplicate, error bars represent 1 S.D..
Figure 2.1B: Plot of external standard response (n=3) versus concentration for acetylcarnitine
and acetylcarnitine-D3, samples analyzed by LC/MS flow injection analysis with precursor ion
scan mode for the production of 85 m/z

Legend: Each sample analyzed in triplicate, error bars represent 1 standard deviation
Figure 2.2A: Plot of calculated response factors (n=3) for external standards containing
carnitine and carnitine-D9, evaluated at five different concentrations, samples analyzed by
LC/MS flow injection analysis with precursor ion scan mode for the production of 85 m/z
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Legend: Each sample analyzed in triplicate, error bars represent 1 standard deviation
Figure 2.2B: Plot of calculated response factors (n=3) for external standards containing
acetylcarnitine and acetylcarnitine-D3, evaluated at five different concentrations, samples
analyzed by LC/MS flow injection analysis with precursor ion scan mode for the production of
85 m/z
The response factors in extracted dried blood spot samples were evaluated using the
flow injection analysis technique described above. Internal standard stock solutions were
prepared in the appropriate solvent identified by Cambridge Isotopes and diluted 200-fold in
the extraction solvent to achieve the appropriate concentration used in the established
newborn screening method. A 3.0 mm sample was punched from a dried blood spot quality
controls sample and placed in a 96-well plate. Three replicates of each sample were extracted
in 100 µL of methanol with 0.1% formic acid containing labeled internal standards. Samples
were vortexed for 30 minutes vigorously and then 70 µL was transferred to a clean 96-well
plate for analysis. These samples were analyzed by flow injection analysis for acylcarnitines and
amino acids. The calculated concentration was determined using the response ratios with the
appropriate labeled internal standard and then multiplying by the concentration of the internal
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standard and the dilution factor as shown in Equation #2.1. In addition, these samples were
quantitated using an internal calibration curve and the back-calculated concentrations were
used to determine the actual concentration of the analyte in the sample. Using Equation #2.3,
the accuracy of the response factor of 1 was determined for each analyte. The accuracy value
can be then be multiplied by 1 to obtain the actual response factor for the extracted samples
which is reported in Table 2.2.
Table 2.2: Evaluation of response factors for external standards and extracted samples
Analyte

Response
Factors for
External
Standards

Response
Factor for
Extracted
Samples

S.D.

S.D.

%RSD

C0

1.26

< 0.05

1.09

0.0649

5.94%

< 0.05

C2

2.35%

< 0.05

1.53

0.137

8.95%

< 0.05

0.0530

6.69%

< 0.05

1.26

0.148

11.7%

< 0.05

0.906

0.0268

2.96%

< 0.05

1.31

0.0616

4.70%

< 0.05

1.13

0.0344

3.05%

< 0.05

1.27

0.0851

6.70%

< 0.05

C6

1.19

0.0361

3.02%

< 0.05

1.13

0.0772

6.83%

< 0.05

C8

0.905

0.0267

2.95%

< 0.05

0.931

0.120

12.9%

0.249

C10

0.728

0.0283

3.89%

< 0.05

0.713

0.119

16.7%

< 0.05

C12

0.963

0.0287

2.98%

< 0.05

0.883

0.129

14.6%

< 0.05

C14

0.897

0.0251

2.80%

< 0.05

0.829

0.117

14.1%

< 0.05

C16

1.01

0.0299

2.95%

0.0742

0.976

0.114

11.7%

0.315

C18

1.10

0.0471

4.26%

< 0.05

1.16

0.141

12.1%

< 0.05

%RSD

p-value*

0.0238

1.89%

0.642

0.0151

C3

0.792

C4
C5

p-value*

Phe

0.931

0.00694

0.746%

< 0.05

1.29

0.0841

6.50%

< 0.05

Leu/Ile

0.932

0.00461

0.495%

< 0.05

1.22

0.105

8.62%

< 0.05

Tyr

1.16

0.0626

5.42%

< 0.05

1.82

0.120

6.60%

< 0.05

Val

1.15

0.0249

2.16%

< 0.05

1.38

0.0893

6.46%

< 0.05

Cit

1.09

0.0282

2.58%

< 0.05

1.67

0.0503

3.00%

< 0.05

Met

1.08

0.0465

4.32%

< 0.05

1.43

0.0214

1.49%

< 0.05

Three replicates at 5 levels were analyzed (n=15) for externals. Three replicates at 4 levels were analyzed (n=12)
for extracted samples. *p-value was used to test if the mean is different than 1.0 using JMP 9.0.0 software. Bold
p-values indicate significant differences

From our results, it is apparent that the response factors determined for external
standards are different than the response factors determined for extracted samples for all
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analytes except C6, C8, C10, C16 and C18, indicating that matrix does affect the response
factors. In addition, the response factors for most analytes and internal standards are
significantly different from one using a two tailed t-test (p < 0.05). Overall, the response factors
for external samples appear to be very consistent with %RSDs less than 6.69%; however,
response factors for extracted samples are much more inconsistent with %RSDs as high as
16.7% for some analytes. Since the responses are not equal for analytes and internal standards,
concentrations of analytes would not be proportional to the internal standard at the same
concentration, thus resulting in values that are lower or higher than the actual concentration in
the sample. Further, if the slope of the analyte response versus concentration is significantly
steeper than that of the internal standard, then small changes in analyte concentration may
result in relatively large quantification errors. Therefore, when samples are analyzed by flow
injection analysis using only response factors, there is a deviation from the actual value when
analyte response factors are different from their internal standard. For instance, the response
factor for C5 was determined to be 1.27 so the calculated concentration is 21.3% lower than
the actual concentration. This indicates that using the concentration of the internal standard
has the potential to inaccurately quantify analytes when the response factors are significantly
different from one.
2.3.2 Flow injection analysis ionization suppression evaluation
One major problem reported with electrospray ionization is matrix related ionization
suppression (Matuszewski, Constanzer, & Chavez-Eng, 2003; Trufelli et al., 2011). As shown
previously, the response factors for external samples are different from extracted samples,
which is a result of competing ionization between the analytes and other components found in
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the extracted sample. When analyzing samples by flow injection analysis there is no separation
between matrix components and the analytes. In addition analytes at higher concentrations
compete for ionization with other analytes reducing their response which could potentially
cause an analyte to be undetected. Using labeled internal standards reduces problems with
quantification related to matrix effects; however sensitivity can be dramatically affected
(Trufelli et al., 2011).
In order to evaluate ionization suppression or enhancement, a post injection infusion
experiment for acylcarnitines and amino acids was conducted using a standard technique
(Matuszewski et al., 2003; Trufelli et al., 2011). First a sample was injected into the mobile
phase flow without post column infusion to determine the lag time between the injection and
the start of the sample plug and to determine time duration of the flow injection profile. The
lag time is related to the flow rate and dead volume of the system, which is dependent on the
tubing length and the tubing diameter. The flow injection profile of the sample appears as a
broad peak since there is not any chromatographic separation. After determining the profile
for the flow injection analysis; matrix effects could be evaluated by infusing an external
standard containing acylcarnitines and amino acids labeled internal standards(20 µL/min), at a
200-fold dilution of the stock solution, in the flow path to the mass spectrometer prior to the
electrospray source. This provides an elevated baseline response for transitions associated
with each labeled internal standard. The labeled internal standards were used to assess matrix
effects, since all blood samples will contain endogenous levels of amino acids and acylcarnitines
which could artificially elevate or suppress the baseline. Next, dried blood spot sample
extracted in methanol with 0.1% formic acid without internal standard are injected onto the
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system. Shifts in the baseline would indicate regions of ion suppression (a negative response
shift) or ion enhancement (a positive shift in the baseline). Matrix effects were evaluated for
six donor blood samples containing endogenous levels of acylcarnitines and amino acids and at
3 fortified levels. To quantify the degree of ion suppression, the average internal standard
responses were evaluated during the flow injection profile and compared to the average
internal standard response obtained by direct infusion with mobile phase.
A representative extracted unfortified sodium heparin human dried blood spot sample
analyzed by flow injection without infusion of internal standard solution is shown in Figure
2.3A. This represents the flow injection profile for a typical sample. A representative extracted
unfortified sodium heparin human dried blood sample analyzed by flow injection with infusion
of internal standard solution is shown in Figure 2.3B. It is apparent from this experiment that
there is a dramatic decrease in ionization during the time that the plug of sample is being
analyzed. The overall decrease in ionization was calculated for each analyte at 4 different levels
in triplicate and average overall suppression was determined to be 63%. For some analytes the
matrix suppression was as high as 78% which could dramatically affect the detectability of
analytes by flow injection resulting in potential misidentification of a metabolism disorder. In
order to reduce this matrix effect and improve sensitivity of this analysis, some form of
chromatographic separation or sample clean-up is necessary.
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Normalized Response

TIC

0.12

0.24

0.36

0.48

0.60

0.72

0.84

0.96

1.08

1.20

1.32

TIC
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0.24

0.36

0.48

0.60

0.72

0.84

0.96

1.08

1.20

1.32

Time (min)

Figure 2.3: TIC of a precursor ion scan for production of 85 m/z, by flow injection analysis of
extracted dried blood spots, A – Flow injection analysis of an unfortified sodium heparin
blood sample without infusion of internal standards, B – Flow injection analysis of a
unfortified sodium heparin blood sample with infusion at 20 µL/min of labeled internal
standards solutions at a 200-fold dilution to assess matrix effects
2.3.3 Chromatographic separation of amino acids and acylcarnitines
Preliminary investigations involved optimization of chromatographic conditions to
achieve acceptable retention of all analytes in a 3.1 minute total injection cycle time. Mobile
phase A contained water with 0.1% formic acid and mobile phase B contained a mixture of 90%
acetonitrile and 10% water, such that the final buffer concentration was 10 mM ammonium
formate. A gradient elution was employed from 96% mobile phase B to 55% mobile phase B
over 1.65 minutes (Table 2.3). An Acquity UPLC pump was used to control the mobile phase
flow at 0.3 mL/min and mobile phase composition allowing for the gradient elution of analytes.
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Representative chromatograms of a single injection of an extracted sample using this gradient
elution is presented in Figure 2.4. Scheduled MRMs were set based on the retention times of
the analytes and then allowing for 0.2 min retention time shift in either direction. Acceptable
separation of the isomers leucine, isoleucine and hydroxyproline was achieved; however C4 and
C5 isomers were not separated under these conditions.

Table 2.3: Chromatographic conditions for separation of acylcarnitines and amino acids
Time (min)

Flow Rate (mL/min)

%A

%B

Initial
1.65
1.66
3.10

0.30
0.30
0.30
End

4
45
4

96
55
96
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Legend: A: C18, B:C16, C:C14, D:C12, E:C10, F:C8, G:C6, H:C5, I:C4, J: Phenylalanine, K: (1)Leucine,
(2)Isoleucine, (3) Hydroxyproline, L:C3, M:Methionine, N:Tyrosine, O:C2, P:Valline, Q:Carnitne,
R:Citrulline

Figure 2.4: Chromatographic separation of 12 acylcarnitines and 8 amino acids with using
gradient conditions shown in Table 2.3 and scheduled MRM transitions for each analyte
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2.3.4 Chromatographic separation of C4 and C5 isomers
Additional work was conducted to resolve the C4 and C5 isomers, since we were
unsuccessful in achieving separation on the HILIC Amide column alone. Several different chiral
stationary phases were evaluated to improve this separation; however the cyclodextrin phases
provided the best resolution. Cyclodextrin phases provide unique selectivity in which
interaction is based on inclusion complexation (Singh et al., 2010). Therefore, smaller analytes
with less steric hindrance will form a more stable complex with the cyclodextrin, whereas larger
analytes with more steric hindrance will not complex as strongly.
Separation of the C4 and C5 isomers was optimized using the Astec cyclodextrin guard
column. The percent aqueous was varied from 0 to 10% and with buffer solutions prepared at
a basic pH and an acidic pH. The resolution between each isobar was determined for each
condition using an external standard containing the individual isobars. Figures 2.5 and 2.6
shows the resolution that was determined for each condition for C4 and C5 isomers
respectively. It was apparent that 2-4% mobile phase A provided the best resolution and a
buffer prepared at pH 8.7 was better than a buffer at pH 4.5. The best resolution obtained for
C4 isobars was 0.38 which is not sufficient for baseline resolution. The resolution achieved for
C5 isobars was 0.8 which was better but still not sufficient for baseline resolution. Longer guard
columns could be used however this would increase the analysis time making it impractical for
a rapid second-tier test. Better resolution may have been achievable with smaller particles or
with alpha cyclodextrin instead of the beta cyclodextrin, however these columns are not
commercially available. Therefore it was decided to use the optimized conditions obtained
with the current configuration for the additional research.
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Figure 2.5: Plot of resolution versus % mobile phase A, evaluated for separation of C4
isomers on an Astec CYCLOBOND™ I 2000 guard column using isocratic elution at different
percentages of mobile phase A and with mobile phase B prepared at pH 8.7 and pH 4.5
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Figure 2.6: Plot of resolution versus % mobile phase A, evaluated for separation of C5
isomers on an Astec CYCLOBOND™ I 2000 guard column using isocratic elution at different
percentages of mobile phase A and with mobile phase B prepared at pH 8.7 and pH 4.5
Combining the cyclodextrin phase and HILIC Amide phase provides resolution of 0.83 for
the C5 isobars and a resolution of 0.97 for the C4 isobars. Baseline resolution is defined as a
resolution of 1.5, however a resolution of 1 is acceptable for quantitative analysis (Miller,
2005). The same mobile phase was used for this separation as used for the separation in the
first part with a modified gradient from 0% to 5% mobile phase A over 10 minutes with a flow
rate of 0.3 mL/min. The chromatographic separation of C4 and C5 isomers in an extracted
sample that contains butyrylcarnitine, isobutyrylcarnitine, valerylcarnitine and
isovalerylcarnitine is shown in Figure 2.7. Although baseline resolution was not achieved, the
separation described would allow identification and quantification of the analytes. As stated
previously, longer columns could be used to achieve full resolution of these isomers; however
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the run time would be significantly longer. It was decided to employ the current separation,
because a longer analysis time would not be desirable for a rapid second-tier test. Separation of
these isomers allows for differential diagnosis for short chain acyl-coenzyme A dehydrogenase
deficiency (SCAD) and isobutyryl-CoA dehydrogenase deficiency(IBCD) or isovaleric academia
(IVA), which is not possible with flow injection analysis.
TIC

Legend: A:ISO C5, B:C5, C:ISO C4,D:C4.
Figure 2.7: Chromatographic separation of an extracted dried blood spot sample containing
butylcarnitine (C4) and isobutyrylcarnitine (ISO C4) at 1.2 µmol/L and valerylcarnitine (C5),
isovalerylcarnitine (ISO C5) at 0.96 µmol/L using modified gradient conditions with HILIC
Amide and Astec CYCLOBOND™ I 2000 guard column
2.3.5 Extraction optimization
An extraction optimization experiment was conducted in which samples were extracted
using various concentrations of methanol and water containing 0.1% formic acid. Additional
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experiments were performed using acetonitrile and water containing 0.1% formic acid, and
acetonitrile and water containing 10 mM ammonium acetate. A 3.1 mm spot was punched
from a control sample and extracted in 100 µL of each extraction solution. Three replicates
were analyzed for each extraction solution evaluated. The samples were injected using the
chromatographic conditions described earlier. The response ratios with internal standard were
plotted for each analyte and extraction condition, typical extraction profile curves for
acetylcarnitine (C2), palmitoylcarnitine (C16) and phenylalanine (Phe) using methanol
containing 0.1% formic acid are shown in Figure 2.8. The extraction profiles for all the other
analytes are very similar to these three profiles and are therefore not presented. From these
plots it is apparent that 100% methanol with 0.1% formic acid demonstrated the highest
recovery as compared to the other conditions tested and is a common extraction solution used
for flow injection analysis (Chace, 2001; Chace, 2007). Although there was not a significant
difference between some of the other extraction solutions, it was observed that more aqueous
in the extraction solution caused the samples to appear cloudy. The samples extracted in
acetonitrile mixtures were visibly clearer than the samples extracted with methanol mixtures;
however 20% aqueous is required in order to achieve comparable recovery to 100% methanol
containing 0.1% formic acid. Since methanol containing 0.1% formic acid is commonly used in
newborn screening analysis, we elected to employ this solvent for further investigations.
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Legend: C2-blue diamonds, C16-red squares, phenylalanine-green triangles. Values for phenylalanine
were multipled x2 for graphical purposes. Error bars represent 1 standard deviation for 3 replicates.

Figure 2.8: Plot of response versus % organic to show extraction efficiency of C2, C16 and
phenylalanine from dried blood spots, sample were extracted in different percentages of
methanol and water containing 0.1% formic acid (n=3) and analyzed using 3.1 minute
chromatographic separation and scheduled MRMs
2.3.6 Ionization suppression evaluation for chromatographic separation
Ionization suppression was also evaluated for the chromatographic separation using the
same technique as described earlier. As discussed earlier it is difficult to assess matrix affects
for samples that contain endogenous levels of the analytes of interest. Therefore the labeled
internals were used to assess matrix effects. Dried blood spot samples were extracted in 100
µL of methanol containing 0.1% formic acid and injected using the chromatographic conditions
that were described in section 2.3.3. In order to evaluate matrix effects the labeled internal
standards were infused post column creating an elevated baseline. While it was apparent that
67

some regions in the chromatogram showed some ionization suppression, the complexity of the
chromatogram makes it difficult to quantify the degree of matrix suppression using this
approach. Therefore, an additional experiment was conducted by comparing internal standard
responses in extracted samples to external samples. This experiment was performed for dried
blood spots prepared from six different individuals. Dried blood spot samples were extracted in
triplicate for each individual using an internal standard working solution prepared in methanol
containing 0.1% formic acid. The samples were transferred to a clean 96-well plate and
injected onto the LC/MS/MS system. The responses for the internal standard in extracted
samples were compared to injections of the working internal standard solution. The results for
this experiment showed minimal matrix effects based on the percent differences in responses
of the internal standards in extracted and external samples, shown in Figure 2.9. Overall there
was less than 20% matrix suppression observed for all the compounds except C16 which
showed ionization suppression of 21.5%. All analytes demonstrated less than 5% relative
standard deviations from triplicate analysis of 6 different lots of sodium heparin human whole
blood samples. This is a dramatic improvement over the flow injection analysis in which as
much as 63% ion suppression was observed. There was also a significant improvement for the
relative standard deviation for this chromatographic analysis compared to the flow injection
approach, which could further improve the positive predictive value (PPV) for metabolism
disorders associated with elevated levels amino acids and acylcarnitines.
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Legend: Black bars are extracted samples white bars are external standards. Error bars represent 1 standard deviation.
Figure 2.9: Bar graph to show matrix suppression evaluated by comparison of internal standard responses in external
standards with extracted dried blood spot samples, samples analyzed in triplicate using 3.1 minute chromatographic
separation and scheduled MRMs

2.3.7 Validation of analysis with chromatographic separation
Validation of the chromatographic method included precision and accuracy, linearity
and recovery. Three replicate samples were analyzed on three separate days in order to assess
inter assay precision and accuracy. Prior to validation six different lots of sodium heparin
human whole blood were analyzed to select a matrix that contained the lowest endogenous
levels of analytes and to ensure the levels of analytes were below the reported cut-off values
(McHugh et al., 2011) . The endogenous levels of all analytes were determined using the
method of standard addition to create a four point curve from the amount fortified versus the
response ratios obtained. Acceptable linearity with correlation coefficients greater than 0.9950
were observed for all analytes using linear regression. From the linear regression y = mx + b,
where “y” is the analyte response ratio, “x” is the analyte concentration, “m” is the slope and
“b” is equal to the y-intercept. Using this equation, the concentration in the unfortified sample
can be obtained at the x-intercept where y = 0, x = -b/m. After establishing concentration in
the blank sample the calibration range for each analyte was established by adding the amount
fortified to the blank concentration producing a six point calibration curve. A larger range was
used for calibration curves to allow for quantification above and below the targeted cut-off
values for each analyte. Different regression models and weighting factors were assessed for
each analyte and the best model was chosen based on having the best correlation coefficient
and lowest average percent difference from theoretical. After evaluating multiple models it was
determined that a quadratic fit model with a 1/concentration weighting factor provided the
best results for all analytes. The final calibration range based on the adjusted concentrations is
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shown in Table 2.4. Correlation coefficients for all runs were greater than 0.9950 for all
analytes.
Table 2.4: Calibration range with average correlation coefficients from 3 days

C0
C2
C3
C4
C5
C6
C8
C10
C12
C14
C16
C18
Phe
Leu
Ile
Tyr
Val
Cit
Met

Calibration Range
(µmol/L)
36.4 – 636
16.7 – 257
1.28 – 41.3
0.210 – 10.2
0.160 – 8.16
0.048 – 8.05
0.090 – 8.09
0.090 – 8.09
0.055 – 10.1
0.052 – 8.052
0.076 – 40.8
0.570 – 16.6
91.3 -1291
115 – 715
64.4 -664
61.4 -1261
180 -1180
42.8 -443
15.1 -615

Average Correlation
Coefficient
0.9990
0.9993
0.9989
0.9994
0.9988
0.9982
0.9967
0.9965
0.9968
0.9958
0.9954
0.9951
0.9973
0.9952
0.9982
0.9971
0.9980
0.9966
0.9973

The precision and accuracy for all the analysis of acylcarnitines and amino acids
extracted from dried blood spots were calculated at each of the four concentrations in triplicate
over 3 separate days, the precision was within 9,98% and the accuracy ranged from 85.7% to
108%, as shown in Table 2.5. However, the highest quality control sample for acetylcarnitine
had an accuracy of 78.2%, which is outside the acceptable limit of + 15% based on FDA
guidance for bioanalytical method validation. The overall average accuracy was evaluated for
each analyte by averaging the results from the 4 levels reported in Table 2.5 and is plotted in
Figure 2.10.
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Table 2.5: Precision and accuracy over three days using chromatographic separation and
MRM transitions
Level 1

Level 2

Level 3

Level 4

Mean
(µmol/L)

%RSD

Mean
(µmol/L)

%RSD

Mean
(µmol/L)

%RSD

Mean
(µmol/L)

%RSD

C0

59.4 (101)

3.10%

87.1 (99.6)

2.97%

240 (104)

3.03%

545 (105)

3.25%

C2

23.7 (98)

9.85%

33.7 (93.4)

7.89%

86.0 (89.5)

7.97%

169 (78.2)

5.05%

C3

2.50 (103)

10.9%

4.14 (98.3)

7.39%

12.7 (95.8)

4.83%

28.0 (89.6)

2.91%

C4

0.529 (103)

8.90%

0.934 (97.2)

3.42%

3.08 (95.8)

3.19%

7.20 (93.4)

4.23%

C5

0.412 (104)

8.48%

0.747 (98.9)

4.51%

2.47 (96.8)

2.65%

5.81 (94.4)

3.40%

C6

0.291 (99.8)

2.16%

0.617 (94.7)

0.29%

2.34 (95.4)

2.69%

5.77 (95.3)

2.17%

C8

0.333 (97.2)

6.00%

0.654 (93.0)

4.64%

2.47 (98.7)

2.92%

5.97 (97.8)

3.68%

C10

0.338 (95.3)

7.14%

0.658 (92.2)

3.64%

2.41 (95.9)

3.50%

6.06 (99.1)

3.36%

C12

0.335 (93.9)

3.62%

0.740 (91.4)

2.25%

3.07 (100)

2.07%

7.80 (103)

0.964%

C14

0.283 (91.4)

8.72%

0.604 (90.2)

3.35%

2.43 (98.4)

3.51%

6.18 (102)

1.57%

C16

2.43 (94.7)

13.1%

4.17 (88.4)

7.35%

15.2 (97.8)

1.53%

38.2 (103)

1.48%

C18

1.23 (97.1)

13.2%

1.78 (89.4)

8.43%

5.64 (101)

4.73%

13.3 (104)

2.48%

Phe

123 (98.9)

6.38%

170 (96.3)

5.62%

426 (97.7)

3.45%

903 (94.6)

4.89%

Leu

130 (99.3)

3.47%

151 (96.4)

2.25%

272 (95.2)

1.75%

513 (94.1)

3.87%

Ile

86.7 (101)

5.91%

111(98.8)

5.10%

233 (96.4)

2.46%

498 (99.4)

4.91%

Tyr

124 (97.6)

4.35%

213 (97.3)

8.84%

719 (108)

5.90%

1614 (103)

2.50%

Val

233 (99.6)

7.38%

270 (97.3)

9.07%

488 (98.9)

6.22%

877 (94.7)

5.83%

Cit

51.1 (100)

6.77%

66.7 (97.7)

4.48%

154 (99.8)

3.09%

320 (97.6)

2.96%

Met

31.3 (91.6)

4.98%

51.5 (85.7)

3.79%

197 (104)

5.03%

473 (105)

7.80%

3 replicates for each level on 3 days (n=9). Percent (%) of target values indicated in parentheses
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Legend: Error bars represent 1 standard deviation for the average of the 4 different levels
Figure 2.10: Bar graph for overall average accuracy determined for 12 acylcarnitines and 7 amino acids at 4 levels over three
days, dried blood spots analyzed with 3.1 minute chromatographic separation and scheduled MRM transitions for each
analyte

2.4 Conclusions
In conclusion, a high speed separation for quantification of twelve acylcarnitines and seven
amino acids using the same extracted sample that is analyzed with the non-derivatized
newborn screening method was developed. The method was validated with respect to
linearity, precision and accuracy and recovery. Matrix related ionization suppression evaluated
by post column infusion showed less that and average of 8.24% difference in the response of
the labeled internal standards when comparing the response in extracted dried blood spots to
the response in external standards. However, the responses for C14-d9, C16-d3 and valine-d8
were approximately a 20% lower in extracted samples compared to external standards. Overall
the matrix suppression was dramatically better with the chromatographic separation than for
the flow injection analysis method. Furthermore, the chromatographic separation allows for
assessment of MSUD by separating leucine, isoleucine and hydroxyproline. Alternative
chromatographic conditions can be used to adequately resolve C4 and C5 isomers allowing for
differential identification of additional disorders SCAD, IVA IBMC, which is not possible in the
current newborn screening methods. The overall chromatographic separation can be
conducted in approximately the same time frame as the established flow injection analysis and
with the same sample, eliminating the need for additional sample preparation or
instrumentation (Sweetman, 2001). This method is a major improvement over the current
newborn screening method allowing for differentially diagnoses of multiple disorders and
improved quantification by resolving matrix related interferences. In addition, our method
does not require derivatization of samples and the injection cycle time is approximately the
same as for the flow injection analysis.
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CHAPTER 3

DIRECT ANALYSIS OF DRIED BLOOD SPOTS BY IN-LINE DESORPTION
COMBINED WITH HIGH RESOLUTION CHROMATOGRAPHY AND MASS
SPECTROMETRY FOR QUANTIFICATION OF MAPLE SYRUP URINE
DISEASE BIOMARKERS LEUCINE AND ISOLEUCINE
Drawn from manuscript published in Analytical and Bioanalytical Chemistry 400(2011) 237-244.

3.1 Introduction
Direct analysis of dried blood spots (DBS) for newborn screening (NBS) could
significantly improve the efficiencies of screening laboratories, allowing for reduced sample
handling, decreased material costs and faster analysis. Further, there is the potential for linking
the data analysis directly to the patient, improving data integrity by minimizing any errors
associated with improper sample identification and handling. During our research, devices
based on different technology for automated DBS analysis have been proposed and are now
past the prototype stage (Abu-Rabie & Spooner, 2009; Déglon et al., 2011). In addition, Leap
Technologies has recently released an automated device which allows for in-line desorption of
dried blood spots, similar to the device that we published; however we are not aware of any
studies that have been published using their device. The Leap Technologies device is similar to
our device in that the DBS card is placed in-line with the mobile phase flow from a HPLC system,
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allowing for desorption of analytes from the DBS followed by chromatographic separation.
Other work has shown that direct analysis of DBS is sensitive and practical for analysis of drugs
and their metabolites for clinical pharmacokinetic studies (Déglon et al., 2011; Thomas et al.,
2010; Abu-Rabie & Spooner, 2009; Van Berkel & Kertesz, 2009), however they still require the
addition of internal standard (IS) either into the sample matrix prior to analysis or require a
predetermined disk to be punched from the filter paper card. Other direct sampling
approaches have been reported including the analysis of DBS on filter paper by desorption
electrospray ionization (DESI) (Takáts, Wiseman, & Cooks, 2005) or the analysis of biological
fluids on glass rods by direct analysis in real time (DART) (Cody, Laramee, & Durst, 2005), but
both lack the ability to separate isomers and avoid matrix effects since no chromatographic
separation is involved. To date there has been no reported applications using direct sampling
with chromatographic separation for biomarker analysis related to metabolism disorders.
NBS for metabolism disorders has involved the analysis of DBS for nearly 50 years, a
sample collection technique originally proposed by Robert Guthrie for the analysis of
phenylalanine to identify newborns that suffered from phenylketonuria (Guthrie & Susi, 1963).
Currently more than 50 different disorders can be identified from a NBS card including
metabolism disorders, endocrinopathies, hemoglobinopathies and infectious diseases (Sahai &
Marsden, 2009). Within the first week of life, all newborns have blood collected by a heel prick
and spotted on special filter paper cards. These cards are dried and then shipped to NBS
laboratories for testing. This sample collection technique offers some distinct advantages
including minimal sample collection volume and reduced costs associated with shipping and
storage; it is less invasive than collecting venous samples and minimizes risks associated with
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transmission of some infectious diseases such as HIV (Li & Tse, 2010; Parker & Cubitt, 1999).
Depending on birthrate, a NBS laboratory receives between 350-1500 samples per day and due
to the time sensitive nature of some of these disorders, they must report results as soon as
possible (Chace, 2009). Due to the large workload there is need for automated techniques and
rapid screening methods to quickly identify affected children.
Although the NBS methods for amino acids and acylcarnitines have proven to be
acceptable for identification of several metabolism disorders, there have been reports of a high
number of false positives results (Sahai & Marsden, 2009), additional confirmation testing
required (Matern et al., 2007) and an inability to differentially identify certain disorders (Chace
et al., 2003). The widely used analysis of acylcarnitines and amino acids employs an extraction
with butyl esterification followed by flow injection LC/MS/MS analysis. Even though this
technique allows for rapid screening, it lacks the ability to differentiate isobaric biomarkers
(Sweetman, 2001; Matern et al., 2007; Bennett, 2009). Maple Syrup Urine Disease (MSUD), a
condition that results in the accumulation of branched-chain amino acids, is often misdiagnosed
by newborns screening method since leucine, isoleucine and hydroxyproline are unresolved
and a second-tier test is required for confirmation of this specific disorder (Matern et al., 2007).
It has been reported that nearly 0.1% of all NBS samples have elevated levels of
leucine/isoleucine/hydroxyproline and require additional testing for proper diagnosis (Matern
et al., 2007). Amino acid analysis typically involves some form of derivatization and
chromatographic separation to resolve these isobaric species by either HPLC UV (Fekkes, 1996;
Pappa-Louisi, Nikitas, Agrafiotou, & Papageorgiou, 2007), UPLC/MS (Boogers, Plugge,
Stokkermans, & Duchateau, 2008), CE-MS (Soga, Kakazu, Robert, Tomita, & Nishioka, 2004) or
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GC/MS (Kaspar, Dettmer, Gronwald, & Oefner, 2008), thus requiring the need for additional
instrumentation, operators and costly consumables.
We have developed a rapid in-line analysis of dried blood spots using a novel device
coupled with a HILIC Amide chromatographic separation that is capable of resolving leucine,
isoleucine and hydroxyproline in a 5 minute total analysis time. Direct analysis is performed
without any offline sample preparation, eliminating the need to punch disks from the filter
paper card or adding internal standard to the dried blood spot. HILIC Amide is a polar
stationary phase with an amide functional group bonded to the silica that allows for better
retention of hydrophilic species than conventional reverse phase columns. This
chromatographic separation eliminates the need for derivatization to resolve these isomers and
mass spectrometry detection provides enhanced selectivity over HPLC UV and HPLC FLD. Our
technique allows for the assessment of MSUD by direct analysis of the original dried blood spot,
reducing analysis time and eliminates the need for collection of additional samples from the
newborn. Further, this methodology shows the ability to directly analyze dried blood spots for
quantification of biomarkers related to metabolism disorders, an advancement that could
greatly improve the efficiencies of newborn screening.
3.2 Materials and methods
3.2.1 Materials and reagents
Amino Acid Reference Standard, 1 nmol/µL in 0.1 N HCl was purchased from Agilent
Technologies (Santa Clara CA, USA). Stable isotope labeled amino acid reference material was
obtained from Cambridge Isotopes (Andover, MA, USA). Hydroxproline was obtained from
ARCOS Organics (Morris Plains, NJ, USA). HPLC grade acetonitrile, formic acid and ammonium
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formate were from Fisher Scientific (Pittsburgh, PA, USA). Dye solution part # 716000765-1 was
obtained from Waters Corp. (Milford, MA, USA). Control human sodium heparin whole blood
was obtained from Biochemed (Winchester, VA, USA). Newborn screening cards, 903 Protein
Saver, were obtained from Whatman (Piscataway, NJ, USA). A 22 Multiple Syringe Pump from
Harvard Apparatus (Holliston, MA, USA) and a 250 µL Hamilton gas tight syringe from Fisher
Scientific (Pittsburgh, PA, USA) was used for infusion tests. Digital images and measurements
for seal integrity evaluation were made with a VHX Digital microscope from Keyence (Itasca, IL
USA).

3.2.2 Chromatographic and instrumentation
Chromatographic separations were conducted with a Waters Acquity HILIC Amide
column (2.1 x 100 mm, 1.7 µm) Waters Corp., (Milford, MA, USA). A Waters Acquity UPLC
pump and sample manager were used for analysis for gradient separation and for controlling a
Rheodyne, 2 position 10-port switching valve purchased from Analytical Sales (Pompton Plains
NJ, USA). The prototype direct sampling device was machined to hold two end caps from a
pre-column filter holder and two 0.5 µm frits from Chrom Tech Inc. (Apple Valley, MN, USA).
End caps were tightened using a Proto 6169A dial torque wrench from Stanley Proto Industrial
Tools (Conyers, GA, USA).

3.2.3 Mass spectrometry conditions
A Waters Premier triple quadrupole mass spectrometer (Milford, MA, USA) equipped
with an electrospray ionization (ESI) source in the positive ion mode was used. Optimization of
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the instrument parameters including desolvation temperature, source temperature,
desolvation gas flow, cone gas flow, capillary voltage, cone voltage and collision energy was
performed by direct infusion of a solution containing leucine, isoleucine and leucine-d3.
Optimal sensitivity was achieved using 4.0 kV for the capillary, 18.0 V for the cone, and 14 eV
for the collision energy. The desolvation temperature was 375 oC using nitrogen as the
desolvation gas at a flow of 800 L/hr. Cone gas was nitrogen at a flow of 20 L/hr with a source
temperature of 110 oC. Argon was used for the collision gas at a flow of 0.2 L/hr. Multiple
reaction monitoring (MRM) from 131.6 m/z to 85.75 m/z was used for leucine and isoleucine
and 134.6 to 88.8 m/z was used for leucine-d3 internal standard. A 0.1 second dwell time was
used for each transition with a 0.02 second inter-scan delay for a total cycle time of 0.27
seconds.

3.2.4 Preparation of dried blood spots
For the validation portion of this study, sodium heparin human whole blood was
fortified at 3 levels (100 nmol/mL, 150 nmol/mL and 250 nmol/mL) using a 1.0 nmol/µL Amino
Acid Reference Standard purchased from Agilent Technologies. Fortified samples were
prepared in volumetric flasks by diluting the appropriate volume of amino acid reference
standard (1.0 nmol/µL) with whole blood and thoroughly mixed. For the validation 55 µL of
each fortified sample along with a blank was spotted onto Whatman, 903 Protein Saver
newborn screening cards. Samples were allowed to dry at room temperature for 2 hours and
stored at 0-5 oC prior to analysis.
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3.3 Results and discussion
3.3.1 Design of device
This device allows for direct sampling of NBS cards without any offline preparation,
eliminating the need to add internal standard or punching a predetermined-size disk from the
dried blood spot. Direct analysis of NBS cards would allow for sample identification to be
directly linked to sample analysis via a bar code reader, with the bar code being on the card
itself, minimizing identity errors associated with transfer of the punched out spot to a tube or
well if the disks are removed from the screening card. NBS cards are placed directly in the flow
path of the liquid chromatograph eluent so that analytes can be desorbed from the card and
chromatographically resolved on an analytical column. The prototype device was machined to
hold two in-line frit end caps such that they could be placed on either side of the newborn
screening card and tightened, forming a leak free seal. In addition this device allows for
different diameter frits to be used so that the sample size could be varied if needed, however
for our experiments we used a 1.5 mm x 0.5 µm frit. Figure 3.1 shows the prototype device
that was used.
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B

A

Mobile Phase

Legend: A: two in-line frit end caps are used with 0.5 µm frits and a slit allows for screening cards to be
placed in the flow path, B: Frit end-caps are tightened forming a leak free seal so that eluent can be used
to elute analytes from the filter paper card

Figure 3.1: Schematic of prototype in-line desorption device showing direct analysis of dried
blood spots
3.3.2 Seal integrity investigation
Infusion of a dye solution through the device containing a blank card was used to assess
the seal integrity of the device. The end caps containing the in-line frits were tightened to
various applied torques to determine how pressure influences the sealing attributes. In
addition we evaluated high and low concentrations of organic solvent in the solution to
determine if there was any impact related to solvent viscosity. A Harvard Apparatus syringe
pump, with a 250 µL Hamilton gas tight syringe, was used to control the flow of the dye
solution through the device. The solution was infused through the device at a 100 µL/min flow
rate with either a 30 second or 1 minute analysis to simulate the intended operation conditions.
Dye solutions of 50% acetonitrile or 90% acetonitrile were evaluated. End caps were tightened
using a dial torque wrench at various torques from 30 to 60 in-lbs. A torque of 30 in-lbs was the
minimum torque that could be applied to firmly hold the card in place and a torque of 60 in-lbs
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was the maximum torque that could be applied without damaging the card from shearing
forces. Therefore, it was decided to use this range to evaluate the seal integrity of the device.
A digital microscope was used to take measurements of the inside and outside diameters of the
frit, along with the diameter of bleed that appeared on the filter paper. Images shown in
Figures 3.2A and 3.2B present the dimensions for the 0.5 µm in-line frit and images 3.2C and
3.2D were obtained when infusing a 50% acetonitrile solution or a 90% acetonitrile solution,
respectively. Three replicates were analyzed under each condition at various torque settings,
to evaluate reproducibility of this technique; data is plotted showing the bleed diameter for
both dye solutions, Figure 3.3. The measurements for the inner and outer diameters of the frit
are represented by gray boundary lines shown on the graph.
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A

B

Diameter
1.43 mm

Inside Diameter

C

Diameter
6.58 mm

Outside Diameter

D

Diameter
2.86 mm

50% Acetonitrile

Diameter
4.24 mm

90% Acetonitrile

Legend: A, B Digital microscope images of 0.5 µm inline frit used and representative images for a
solution with C 50% acetonitrile and D 90% acetonitrile showing the bleed diameters obtained

Figure 3.2: Digital microscopic images for 0.5 µm in-line frit and filter paper samples showing
the bleed diameter for a dye solution containing either 50% acetonitrile or 90% acetonitrile
infused at 100 µL/min for 1 minute
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Legend: Top and bottom boundary lines in grey indicate the inside and outside diameter of the inline
filter. Error bars represent 1 S.D. from three replicates.

Figure 3.3: Plot of the bleed diameter by direct infusion of a dye solution containing either
50% acetonitrile or 90% acetonitrile through the in-line desorption device at 100 µL/min for 1
minute

ANOVA with a student t-test was used to compare the variances and means for the
bleed diameters of each solution at the different applied torques. The results indicate that
there is not a significant difference in bleed diameter for different applied torques; 90%
acetonitrile p > 0.057 and 50% acetonitrile p > 0.2395. The average bleed diameter observed
for 50% acetonitrile solution was 3.13 mm and for the 90% acetonitrile solution it was 4.73 mm.
Although the bleed diameter was larger for the solution containing 90% acetonitrile, all of the
results were within the outside diameter of the frit indicating that a leak free seal was achieved.
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In addition, the results showed acceptable reproducibility with relative standard deviations
(RSD) less than 6.86% for all experiments except for the 50% acetonitrile at 50 in-lbs which
demonstrated a RSD of 18.9%. The results indicate that an acceptable seal was achieved and no
bleed exceeded the outside diameter of the frit with the values of torque studied. Since the
bleed was contained within the dimensions of the frit and did not disturb the remaining portion
of the sample, multiple analyses can be performed from a single dried spot. Based on the 6.6
mm outside diameter of the frit and the 13 mm dried blood spots, three measurements can be
made from a single dried blood spot. In addition, the Whatman, 903 Protein Saver newborn
screening cards appear to withstand the solvents used and do not deteriorate under these
conditions.

3.3.3 Elution profile for leucine and isoleucine from dried blood spots
In order to determine the optimal elution conditions for leucine and isoleucine, by direct
analysis of the DBS, various mixtures of eluent were evaluated using a flow rate of 0.1 mL/min.
In addition, the elution solvent needed to be appropriately matched to the chromatographic
separation, in order to achieve acceptable retention of leucine and isoleucine. Hydrophilic
interaction chromatography (HILIC) employs a polar stationary phase with a normal phase
separation mechanism in which the aqueous mobile phase is the stronger elution solvent and
the organic mobile phase is the weaker elution solvent. Therefore, a higher concentration of
aqueous will result in less retention of the analytes on the HILIC analytical column reducing the
chromatographic performance of the column. Optimal retention of compounds is achieved
with organic concentration greater than 50%. Mobile phase A contained 10 mM ammonium
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formate with 0.1% formic acid and mobile phase B contained a mixture of 90% acetonitrile and
10% water, such that the final buffer concentration was 10 mM ammonium formate. For
elution optimization, we evaluated various percentages of mobile phase A, the aqueous
component, from 5% to 35% to determine elution profiles of leucine and isoleucine. No
chromatographic separation was used for this portion so that the elution profile could be
analyzed independent of chromatographic performance. The 2-position 10-port switching
valve was switched to elute the analytes at 0.25 minutes and data was collected for 3 minutes
using multiple reaction monitoring (MRM) of the 131.7 to 85.8 m/z, the specific mass transition
for leucine and isoleucine. Figure 3.4 shows the elution profiles obtained under the various
conditions tested.
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Normalized Response

Time (min)
Figure 3.4: Elution profiles for leucine and isoleucine from dried blood spots using in-line
desorption device, mobile phase flow rate set to 0.1 mL/min and evaluated isocratic elution
with 5%, 15% , 25% and 35% aqueous
The plots indicate that the majority of the analytes elute within the first minute, from
0.25 minutes to 1.25 minutes, under all elution solvents tested. However, the plots show that
some residual analyte continues to elute out past 3 minutes. Further evaluation of the profiles
show differences in the absolute response varied between the elution solvents. There are
several possible factors that could contribute to these differences, such as solvent desorption
strength, matrix suppression and ionization efficiency. Overall the elution profiles appeared to
be similar and only slight differences are seen in the residual level of analyte eluted after 3
minutes. Based on these results a one minute elution would be acceptable and additional
elution time does not provide significant gains. Further elution time impacts the loading
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volume placed on the chromatographic column, increasing this volume can dramatically impact
chromatographic performance and in order to minimize the overall analysis time the elution
time should be as short as possible.
3.3.4 Chromatographic optimization
Preliminary investigations involved optimization of chromatographic conditions to
achieve separation between leucine, isoleucine and hydroxyproline. Mobile phase composition
was the same as described above, but for this a gradient elution was employed from 90%
mobile phase B to 75% mobile phase B over 1.6 minutes shown in Table 3.1. An Acquity UPLC
pump was used to control the mobile phase flow and mobile phase composition allowing for a
gradient elution of analytes. Resolution was assessed for the separation of leucine and
isoleucine and was determined to be approximately 1.2. Separation between two closely
eluting peaks is determined to be acceptable when the resolution is greater than 1 (Miller,
2005).
Table 3.1: Initial Chromatographic conditions without in-line desorption device
Time (min)
Initial
1.60
2.70
2.75

Flow Rate
(mL/min)
0.35
0.35
0.35
0.35

%A

%B

10
25
25
5

90
75
75
95

The next step was to incorporate the on-line desorption device prior to the HILIC Amide
separation to assess chromatographic performance for direct analysis of DBSs. In order to
include the desorption device the gradient was modified to include both the desired switching
interval, elution time and ratios of mobile phase A and B. The same gradient profile and slope
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used to chromatographically elute the analytes was adjusted based on elution time either with
a 30 or 60 second delay. Three different elution conditions were evaluated to determine
impact of elution time and aqueous concentration on chromatographic performance. We
evaluated a 30 second elution with 90% mobile phase B, a 60 second elution with 90% Mobile
phase B and a 60 second elution with 95% mobile phase B; the results are shown in Figure 3.5.
The resolution for the three conditions was evaluated and was determined to be 1.2 for both
the 30 second elution and 90% mobile phase B and for 60 second elution and 95% mobile phase
B. The resolution was 1.1 for the 60 second elution and 90% mobile phase B elution. Although
acceptable resolution was achieved for a 30 second elution with 90% mobile phase B, the
response was approximately 40% lower than with a 60 second elution time. However,
resolution between leucine and isoleucine was not as good with a 60 second elution with 90%
mobile phase B. The best resolution and response was obtained for a 60 second elution with
95% mobile phase B, Table 3.2 shows the final gradient program used.
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Normalized Response

Time (min)
Legend: A: 30 second elution 90% mobile phase B; B: 60 Second elution 90% mobile phase B; C: 60
second elution 95% mobile phase B

Figure 3.5: Chromatographic separation on HILIC Amide column for leucine and isoleucine
following in-line desorption from a dried blood spot using different elution times and solvent
strengths
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Table 3.2: Final chromatographic conditions with in-line desorption device
Time (min)
Initial
0.04
1.05
1.08
2.50
3.70
3.75

Flow Rate
(mL/min)
0.1
0.1
0.1
0.35
0.35
0.35
0.35

%A

%B

Valve Position

Description

5
5
5
5
20
20
5

95
95
95
95
80
80
95

1
2
1
1
1
1
1

Bi-pass
Load
Bi-pass
Bi-pass
Bi-pass
Bi-pass
Bi-pass

For quantification of leucine and isoleucine an Acquity UPLC autosampler was used to
inject the internal standard working solution which passed through the screening card at the
same time as the analytes are eluted. This timing was optimized by varying the initial switching
time and evaluating the response of the internal standard. The optimal switching time is based
on the dead volume of the system. The dead volume of the system is a measure of the system
volume, which includes all the tubing, including the injection loop between the pump and the
column. This volume can vary dramatically from system to system depending on the pump
type, mixing valves and injection loops. As a hypothetical example; if the dead volume of the
system was 1 mL and the flow rate was 1 mL/min then it would take approximately 1 minute
for the mobile phase to go from the pump to the column. However, if the dead volume was 2
mL then it would take 2 minutes for the mobile phase to reach the column. For our purposes
we were concerned about the volume between the autosampler and the device, so we
optimized the switching time so that the internal standard would reach the device at the same
time as the valve was switched. Systems with a larger dead volume will require additional time
for the internal standard to reach the device and systems with a smaller dead volume will not
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require as much time. This technique allows for quantification of leucine and isoleucine without
pretreatment of the NBS card with internal standard. For the analysis, 10 µL of internal
standard working solution, 6.25 nmol/mL, was injected onto the LC/MS system allowing for 4
times as many samples to be processed with the internal standard working solution compared
to the current newborn screening method, resulting in significant cost savings. Figure 3.6 shows
the final chromatographic separation employing the on-line desorption device and with elution
using the internal standard. The internal standard, Leucine-d3, elutes at approximately the
same time as leucine.

Normalized Response

A

134.6 > 88.8

B

131.6 > 85.7

Time(min)
Legend: A: leucine-d3 at 3.42 min; B: leucine at 3.41 min, isoleucine at 3.53 min and
hydroxyproline at 4.29 min.
Figure 3.6: Final chromatographic separation for leucine, isoleucine, hydroxyproline and
leucine-d3 using in-line desportion device and a HILIC Amide column
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3.3.5 Validation of device for quantification of leucine and isoleucine
Validation included both intra spot precision and accuracy, inter spot precision and
accuracy, linearity, recovery and post column infusion for matrix suppression. Three replicate
samples were analyzed from a single spot across three separate days in order to assess intra
spot precision and accuracy. Inter spot precision was assessed by analyzing one replicate from
3 different spots on a single day. Since human whole blood contains endogenous levels of
leucine and isoleucine, the concentration in the blank was determined first. Quantification of
the endogenous levels was performed using the method of standard addition to create a curve
from the amount fortified versus the response ratios obtained, shown in Figure 3.7A.
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A

Standard addition plot for leucine

Concentration (µmol/L)

B

Standard addition plot for leucine with addition of endogenous level

Concentration (µmol/L)
Legend: A: Plot based on amount fortified to blood, x-intercept is used to calculate endogenous level found in
whole blood, B: Calculated concentration for a blank was used to determine concentration of fortified levels. Error
bars represent 1 Standard deviation

Figure 3.7: Standard addition plots for leucine generated by the analysis of dried blood spot
samples fortified with leucine at three levels and without fortification in order to quantify
the endogenous level present in samples, all samples analyzed in triplicate
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Regression analysis was evaluated over three days using analyte response ratios with
internal standard (leucine-d3). The response ratios for the unfortified samples and samples
fortified at three concentrations for leucine and isoleucine were plotted versus the fortified
concentration. Linear regression y = mx + b was used to determine the unfortified sample
concentration, where “y” is the analyte response ratio, “x” is the analyte concentration, “m” is
the slope and “b” is equal to the y-intercept. The concentration in the unfortified sample can
be obtained at the x-intercept where y = 0, x = -b/m. Using this concentration we can then
calculate the amount in each fortified level, for example level 1 would be 100 nmol/mL + blank
concentration. The data is then plotted using the calculated theoretical levels for the blank and
each fortified level versus the response ratios, Figure 3.7B. A linear regression was used with a
weighing factor of 1/concentration and back calculated values are determined for each level.
The final calibration range based on the adjusted concentrations were from 128 to 383
nmol/mL for leucine and from 59.9 to 324 nmol/mL for isoleucine. Correlation coefficients (r)
for all runs were greater than 0.9805, except for one run the correlation coefficient was 0.9706
for isoleucine. Precision and accuracy were calculated for each calibration standard on three
separate days for inter spot variability and on one day for intra spot variability. Overall, intra
spot precision ranged from 3.21% to 5.84% for leucine and 4.43% to 9.14% for isoleucine with
accuracy of 92.3% to 105% for leucine and 90.9% to 108% for isoleucine (Table 3.3). Inter spot
precision ranged from 2.38% to 9.98% for leucine and 3.26% to 7.33% for isoleucine with
accuracy of 89.7% to 107% for leucine and 88.0% to 110% for isoleucine (Table 3.4).
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Table 3.3: Intra spot precision and accuracy for leucine and isoleucine determined by 3
replicates analyzed on 3 different days
Blank
0 nmol/mL

Low Level
100 nmol/mL

128

205

274

383

Average Precision

5.84%

5.05%

3.21%

4.09%

Average Accuracy

105%

92.3%

101%

104%

59.9

141

202

324

Average Precision

9.14%

8.64%

6.17%

4.43%

Average Accuracy

108%

90.9%

98.4%

106%

Fortified Conc.

Mid Level
High Level
150 nmol/mL 250 nmol/mL

Leucine
Average Conc. (nmol/mL)

Isoleucine
Average Conc. (nmol/mL)

Table 3.4: Inter spot precision and accuracy for leucine and isoleucine determined by 1
replicate on 3 different spots analyzed on one day
Blank
0 nmol/mL

Low Level
100 nmol/mL

128

198

275

383

Average Precision

2.38%

9.98%

8.19%

6.46%

Average Accuracy

107%

89.7%

102%

104%

67.8

142

208

333

Average Precision

3.26%

7.33%

3.27%

7.21%

Average Accuracy

110%

88.0%

98.3%

107%

Fortified Conc.

Mid Level
High Level
150 nmol/mL 250 nmol/mL

Leucine
Average Conc. (nmol/mL)

Isoleucine
Average Conc. (nmol/mL)
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Three replicates of a mid-level fortified sample were used to assess recovery. Recovery
was performed by conducting six replicate injections from a single position on a DBS. The peak
areas from each individual injection were summed to provide a total area eluted which was
used as 100% recovery. From this recovery of the first elution could be calculated. Recovery
was determined to be 63.6% for leucine and 65.7% for isoleucine with RSDs within 4.34%.
3.3.6 Matrix suppression evaluated using a post-column infusion technique
A post-column infusion experiment for leucine, isoleucine and leucine-d3 was
conducted to evaluate ion suppression or enhancement due to the matrix (Matuszewski et al.,
2003). A syringe pump was used to continuously infuse (10 µL/min) of an external solution
containing 100 nmol/mL of leucine, isoleucine and leucine-d3 in the flow path to the mass
spectrometer post column. This provided a high baseline response for transitions associated
with each compound so that when matrix is eluted pre-column, ion suppression would appear
as a negative response shift in this high baseline, whereas ion enhancement would appear as a
positive shift. The time duration of these shifts indicate elution times where ion suppression
and enhancement occur. Blank matrix blood spots were eluted using the optimized
chromatographic conditions while monitoring for shifts in the specific mass transitions for the
analytes and internal standard. Figure 3.8, shows a representative chromatogram of a sodium
heparin human blood blank eluted using this post column infusion technique. The initial
negative shift seen at 1.07 minutes is attributed to a change in flow rate from 0.1 mL/min to
0.35 mL/min. This decrease in ionization is due to the increase in flow rate and should not
impact the quantification of the analytes. Additional suppression shifts in the chromatogram
were observed throughout the separation for both the analytes and internal standard channels.
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As previously discussed it is difficult to assess matrix affects in samples that contain
endogenous levels of the analytes of interest. In these dried blood spot samples, peaks for
leucine and isoleucine were observed (Figure 3.8B) at the expected retentions for leucine and
isoleucine, due to the endogenous levels in human whole blood. Therefor the internal standard
transition was used to assess matrix affects. The greatest suppression is less than 20% of the
total peak response for leucine and isoleucine.

A

B

Legend: A: Mass transition for leucine-d3, internal standard 134.6 > 88.8. B: Mass transition for leucine
(3.30 min) and isoleucine (3.41 min) 131.6 > 85.7. Flow rate adjusted from 0.1 mL/min to 0.35 mL/min
at 1.07 minutes resulting in a decrease in ionization.

Figure 3.8: Matrix suppression evaluation for analysis of a dried blood spot sample using the
in-line desportion device and chromatographic separation on the HILIC Amide column, postcolumn infusion of leucine, isoleucine and internal standard at 100 nmol/mL
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3.4 Conclusions
In conclusion, direct analysis of dried blood spots using a prototype device was applied
to the quantification of biomarkers for MSUD. Work has been presented that shows that this
device provides a leak free seal allowing for direct analysis of DBSs eliminating the need for any
offline sample preparation. The method was validated and provides good precision and
accuracy for leucine from 128 to 383 nmol/mL and isoleucine from 59.9 to 324 nmol/mL
appropriate concentration ranges for identification of MSUD. Direct analysis provides several
advantages over current second-tier tests for MSUD in that there is no need for derivatization,
analysis can be done with the addition of the device to current instrumentation and direct
analysis can be conducted with original dried blood spot. This prototype design could be easily
automated using conventional robotics, which would allow for hundreds of samples to be
processed with minimal human intervention, greatly improving the efficiency of newborn
screening.
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CHAPTER 4

A NOVEL ON-CARD APPROACH FOR DETERMINING HEMATOCRIT OF
DRIED BLOOD SPOTS ALLOWING FOR CORRECTION OF SAMPLE
VOLUME

4.1 Introduction
Analysis of dried blood spots has been used in newborn screening for decades and more
recently it has become increasingly applied in bioanalytical analysis of pharmaceuticals for new
drug development and for therapeutic drug monitoring (Denniff & Spooner, 2010; Edelbroek et
al., 2009; O'Mara, Hudson-Curtis, Olson, Yueh, Dunn, Spooner, 2011). This sample collection
technique offers many advantages including minimal sample collection volume, reduced costs
associated with shipping and storage, it is less invasive than collecting venous samples and
minimizes risks associated with transmission of some infectious diseases such as HIV (Li & Tse,
2010; Parker & Cubitt, 1999) Despite the numerous advantages to this sample collection
technique, the most common concern is how to correct for sample volume variations.
Hematocrit, which is a measure of concentration of red blood cells per unit volume of blood,
has the largest influence on the sample volume for dried blood spot analysis. This is primarily
due to the viscosity of blood being greater at high hematocrit and less at low hematocrit
(Edelbroek et al., 2009). When blood is applied to filter paper, the blood will diffuse at different
rates for blood samples with low and high hematocrits affecting the size of the blood spot
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(Adam et al., 2000; Denniff & Spooner, 2010; Edelbroek et al., 2009; Mei et al., 2001). Since a
fixed punch size is used for sample analysis, the sample amount is dependent on hematocrit
and it can be significantly different in cases of abnormally low and high hematocrit (Denniff &
Spooner, 2010; Mei et al., 2001). Typical hematocrit ranges from 28–67% in most healthy
individuals and the normal range for newborns is from 42-64% (Denniff & Spooner, 2010).
However, abnormal hematocrit can be characteristic of polycythemia or anemias, causing high
and low hematocrit respectively. Several publications have reported the effects of hematocrit
on concentration of pharmaceuticals (Denniff & Spooner, 2010; Wilhelm et al., 2009) and
amino acids and acylcarnitines (Holub et al., 2006) in dried blood spots. In addition, some
compounds show a chromatographic effect, where the concentration of the analyte is higher in
a center punch relative to a peripheral punch (Holub et al., 2006; O'Mara, Hudson-Curtis,
Olson,Yueh, Dunn, Spooner, 2011). Others have reported minimal differences in sample
volume relative to normal hematocrit levels (Denniff & Spooner, 2010). It is difficult to
accurately quantify sample volume unless a predefined volume of blood is spotted on filter
paper and the whole spot is analyzed. Edelbroek has reviewed several publications using this
technique which eliminates issues with hematocrit variations (Edelbroek et al., 2009). Although
this approach may work for clinical analysis or therapeutic drug monitoring, it is not practical
for newborn screening.
Newborn screening relies on a simplistic approach of spotting whole blood from a heal
puncture on the filter paper and the sample volume is approximated at 3.1 µL from a 3 mm
punch (Holub et al., 2006). In most cases the identification of a specific disorder is fairly
distinguishable however; there are times when correction for volume could mean the
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difference between a test positive and a test negative result (Holub et al., 2006; Orsini et al.,
2010). Routine DBS analysis has been shown to be acceptable for newborn screening for
decades but, there is still the potential to further improve the positive predictive value of this
test. Since cut-off values are set independent of hematocrit the potential to misidentify
samples is increased with high or low hematocrit samples. It has been reported that sample
volume in DBS analysis can vary by as much as 47% depending on the hematocrit (Mei et al.,
2001). A recent study evaluated the effect hematocrit has on the measured concentration of
succinylacetone, which showed that samples with low hematocrit quantitated approximately
45% low and samples with high hematocrit quantitated 24% higher than expected (Peng, Liu, &
Peng, 2012). Hematocrit effects on the analysis of amino acids and acylcarnitnes, markers for
organic acid disorders, amino acid disorders and fatty acid oxidation disorders has been
reported (Holub et al., 2006). Holub showed a positive correlation between analyte
concentration and hematocrit. A chromatographic effect for some analytes showed significant
differences in their concentration between peripheral and center punches (Holub et al., 2006).
Attempts have been made to correct for differences in hematocrit using hemoglobin variant
testing to approximate sample volume (Orsini et al., 2010) Orsini reported an average accuracy
of 108% using this technique, however the results ranged from 73.5% to 142% (Orsini et al.,
2010).
UV and NIR spectroscopy has been used for years to evaluate the composition and
properties of blood in vitro and in vivo (Johns et al., 2001; Meinke et al., 2005; Schmitt et al.,
1986; Serebrennikova et al., 2008; Steinke & Shepherd, 1986; Steinke & Shepherd, 1988; Zhang
et al., 2000; Zijlstra et al., 1991; Zonios & Dimou, 2006). Several models and theories have been
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used to explain the light scattering, absorption and reflectance properties of whole blood to
determine hemoglobin concentration, hematocrit and blood oxygenation levels. Many of these
theoretical models have resulted in medical devices used by health care providers including
oximeters (Schmitt et al., 1986; Steinke & Shepherd, 1986) and hemoglobinometers ( Zhang et
al., 2000). These devices offer several major advantages over other sampling techniques
including: nondestructive analysis, less invasive sampling, portable instrumentation and faster
analysis time.
Analysis of whole blood in vivo and in vitro solutions has several complexities, due to
the nature of the medium and other biological factors. Several different models and theories
have been used to explain the properties of blood either in vitro or in vivo. Mie theory
supports the light scattering properties of whole blood to evaluate red blood cell size and
concentration in dilute solutions (Steinke & Shepherd, 1988). Although there has been some
criticism to using Mie theory due to the shape of the red blood cells not being spherical,
experimental results were comparable the theoretical predictions. Absorption measurements
have been reported to be inversely proportional to reflectance of blood in thin films of nonhemolyzed blood and reflectance increases with increasing the thickness of the film (Anderson
and Sekelj, 1967). The absorption properties of whole blood deviates from Beers law at high
concentrations where the optical density does not appear to be related to hemoglobin
concentration nor the path length (Lovell, Hebden, Goldstone, & Cope, 1999). More recently a
paper by Serebrennikova et. al. proposed a new theoretical model that uses diffuse reflectance
and light scattering to analyze whole blood (Serebrennikova et al., 2008). From their data it
was apparent that reflectance is related to erythrocyte concentration. Although there are
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many spectroscopic methods used for hematocrit determination for whole blood in vivo and in
vitro, there have not been any published articles related to the spectroscopic analysis of dried
blood spots to determine hematocrit.
We have developed a novel on card approach to evaluate hematocrit on dried blood
spot using diffuse reflectance. Our method is the first reporting using a direct sampling
approach for hematocrit that shows improved precision and accuracy by correcting for sample
volume. Direct analysis by reflectance of can be used to relate sample hematocrit allowing for
volume correction. This technique could be used in newborn screening or clinical analysis
improving the quantification of dried blood spot analysis. Results are presented for
quantitative analysis of acylcarnitines in dried blood spots from donor samples at various
hematocrit levels. Correcting for sample volume is increasingly important to properly identify
children with low hematocrit or high hematocrit.
4.2 Materials and methods
4.2.1 Materials and reagents
Acylcarnitine reference standards were purchased from VU Medical Center Metabolic
Laboratory, (Amsterdam, The Netherlands). Stable isotope labeled acylcarnitines reference
materials were obtained from Cambridge Isotopes (Andover, MA, USA). HPLC grade
acetonitrile, formic acid and ammonium formate were from Fisher Scientific (Pittsburgh, PA,
USA). Control human potassium EDTA whole blood was obtained from Biochemed (Winchester,
VA, USA). Newborn screening cards, 903 Protein Saver and DMPK filter paper cards were
obtained from Whatman (Piscataway, NJ, USA).
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4.2.2 Chromatographic instrumentation
Chromatographic separations were conducted with a Waters Acquity HILIC Amide
column (2.1 x 50 mm, 1.7 µm) Waters Corp., (Milford, MA, USA). A Waters Acquity UPLC pump
and sample manager were used for analysis and gradient separation. A Waters Premier triple
quadrupole mass spectrometer (Milford, MA, USA) equipped with electrospray ionization (ESI)
source in positive ion mode was used. Instrument parameters were optimized for analysis of
acylcarnitines and their labeled internal standards by direct infusion of an external solution into
the mass spectrometer. Optimal sensitivity was achieved using 3.8 kV for the capillary, 390 oC
desolvation temperature with nitrogen as the desolvation gas at a flow of 800 L/hr. Cone gas
was nitrogen at a flow of 20 L/hr with a source temperature of 110 oC. Argon was used for the
collision gas at a flow of 0.4 L/hr. Multiple reaction monitoring (MRM) was used for all analytes
and internal standard. Individual mass transitions for all analytes is shown in Table 4.1.
Optimized MRMs were used based on the retention time of analytes to achieve a minimum 0.4
minute window around each peak with a 0.02 second dwell time and a 0.02 second inter-scan
delay.
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Table 4.1: Acylcarnitines and amino acids analyzed and the mass spectral settings for MRM
mode
I.S. MRM

Time segment

Transition

(min)

C0-D9

170.9→84.6

1.73 to 2.03

203.9→84.6

C2-D3

206.9→84.6

1.57 to 1.87

20

217.9→84.6

C3-D3

220.9→84.6

1.43 to 1.73

22

21

231.9→84.6

C4-D3

235.0→84.6

1.31 to 1.61

C5

22

23

246.0→84.6

C5-D9

255.1→84.6

1.21 to 1.51

Hexanoylcarnitine

C6

22

23

260.0→84.6

C8-D3

291.1→84.6

1.10 to 1.40

Octanoylcarnitine

C8

22

23

288.1→84.6

C8-D3

291.1→84.6

0.97 to 1.27

Decanoylcarnitine

C10

22

28

316.1→84.6

C8-D3

291.1→84.6

0.80 to 1.10

Lauroylcarnitine

C12

22

28

344.1→84.6

C14-D9

381.2→84.6

0.63 to 1.01

Myristoylcarnitine

C14

22

28

372.1→84.6

C14-D9

381.2→84.6

0.63 to 1.01

Palmitoylcarnitine

C16

22

28

400.2→84.6

C16-D3

403.2→84.6

0.00 to 0.95

Stearoylcarnitine

C18

22

28

428.2→84.6

C16-D3

403.2→84.6

0.00 to 0.95

Analyte

MRM

ID

CV (V)

CE (eV)

Carnitine

C0

22

20

161.9→84.6

Acetylcarnitine

C2

22

20

Propionylcarnitine

C3

22

Butyrylcarnitine

C4

Valerylcarnitine

Transition

I.S.

4.2.3 UV/NIR-instrumentation
Dried blood spot samples were analyzed with a QE65000 Scientific-Grade Spectrometer
and deuterium tungsten halogen light source from Ocean Optics (Dunedin, FL). Reflectance
measurements were made with a R400-7-VIS/NIR reflectance probe, Ocean Optics. Data was
collected from 200-1000 nm using a 6 msec integration time and a boxcar smooth setting of 2.
The reflectance probe was held in position using a gripper mounted to a ring stand. A picture of
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the reflectance probe apparatus is shown in Figure 4.1. In order to analyze the samples in
reflectance mode the background of the detector and the sample must be analyzed. First the
background from the detector is accounted for by taking a reference “dark” sample in which
the detector was blocked from all light. Next a reference “light” sample is collected, for this we
used a blank Whatman 903 filter paper card. This was done in order to account for the
inherent background peaks present in the Whatman 903 filter paper that absorb UV/NIR light.
Using the paper as a reference allows for these peaks to be subtracted from the data collected
for reflectance, absorbance and light scattering measurements. Also the ambient light was
reduced by turning off all overhead lights to eliminate background light from interfering with
the analysis. An alternative approach to block out all light would be to move the black collar
around the end of the probe to be flush with the dried blood spot. However, using the collar to
block all light also makes it difficut to see where you are taking measurements, so in order to
make sure we sampled appropiately we elected not to use the collar.
For probe height optimization an adjustable stage was placed below the probe to adjust
the height of the probe above the sample. Following the optimization experiment the
adjustable stage was removed and the probe was fixed at the optimized distance from the base
in order to make optical measurements more consistent.
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Legend: A: Reflectance probe positioned above dried blood spot, B: Expanded view of reflectance probe
set-up showing ring stand holder.

Figure 4.1: UV-reflectance fiber optic probe setup, showing how the probe is held in position
above dried blood spot
4.2.4 Preparation of dried blood spots
Potassium EDTA human whole blood was used to prepare samples at 25%, 35%, 45%,
55%, 65% and 75% hematocrit by first measuring the hematocrit by centrifuging the samples at
3500 rpm for 20 minutes and measuring the volume of red blood cells. The hematocrit was
adjusted by adding or removing serum. The red blood cells were re-suspended by gentle
mixing. For quantitative purposes, individually prepared reference standards containing
acylcarnitines (Carnitine, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16 and C18) were fortified into
the whole blood at approximately ten times the endogenous level. After thoroughly mixing the
samples, 50 µL of unfortified and fortified whole blood samples at the various levels of
hematocrit were spotted on three different lots of Whatman 903 Protein Saver newborn
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screening cards. For DMPK filter paper cards only 15 µL of blood was spotted on filter paper
due to cards are for smaller sample volumes. In addition, 10 µL, 25 µL and 100 µL of the same
samples were spotted on separate Whatman 903 filter paper cards. All samples were allowed
to thoroughly dry at room temperature and then stored at 0-5 oC until analyzed. Figure 4.2 is a
picture of the dried blood spots from 25% hematocrit to 75% hematocrit after drying. There are
some distinct differences observed in the dried blood spots at the various hematocrit levels.
Samples prepared at 25% and 35% hematocrit appear to have a second lighter ring that diffuses
out farther from the center. As the hematocrit level increases to about 45% this ring becomes
less apparent. Samples prepared at 65 to 75% hematocrit appear much darker in color and do
not fill the entire spot with 50 µL of blood.

Figure 4.2: Dried blood spots prepared at various levels of hematocrit, 50 µL of blood was
spotted on Whatman 903 filter paper
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4.3 Results and Discussion
4.3.1 UV reflectance of dried blood spots
For our initial investigations we collected absorbance, reflectance and light scattering
data when the probe was positioned perpendicular to the dried blood spot samples. There did
appear to be some similarities between reflectance and absorbance spectra, however light
scattering alone did not provide identifiable differences between samples at different levels of
hematocrit. The absorbance spectra appears to be the inverse of the reflectance spectra. Since
we are measuring diffuse reflectance which is a measure of both light scattering and
absorbance, we decided to collect the data in reflectance mode; however absorbance could
provide similar results.
4.3.2 Probe height optimization
Since reflectance is related to the intensity of the light we first optimized the probe
position above the sample. The probe height was optimized by measuring the reflectance from
210 to 1000 nm for 25%, 55% and 75% hematocrit dried blood spot samples. The position of
the probe was adjusted from 0 mm to 10 mm from the surface of the spot in 1 mm increments
by raising and lowering an adjustable stage. Triplicate analysis of each sample was performed
at different locations for each hematocrit at 25%, 55% and 75%. Reflectance measurements
were evaluated for several different wavelengths from 200 to 1000 nm. Wavelengths below
800 nm did show provide a relationship between % hematocrit and reflectance, however
wavelengths above 800 nm all had a similar correlation but the slope was larger. A larger slope
provides improved sensitivity for this analysis allowing for better discrimination between
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samples. For this experiment the responses were plotted for 980 nm to show the effect of
probe position above the spot related to reflectance for several hematocrit levels, Figure 4.3.

Legend: Error bars represent 1 standard deviation
Figure 4.3: Optimization of probe height above dried blood spot for reflectance
measurements at 980 nm, evaluated with samples prepared at 25%, 55% and 75%
hematocrit, samples analyzed in triplicate

From our data it was apparent that 3-4 mm above the surface of the probe provided the
highest relative intensity for each hematocrit level. At positions lower than 3 mm the mean
reflectance values for 55% and 75% hematocrit were not significantly different using a t-test,
p = 0.396. Measurements above 4 mm had less intensity which was probably due to the
diffusion of light created by moving the probe farther away from the samples. For this reason
we choose 3-4 mm to evaluate the relationship between percent reflectance and hematocrit.
Figure 4.4 shows a plot for the percent reflectance versus hematocrit plotted for 3 mm and 4
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mm. The correlation coefficient was calculated both 3 mm and 4 mm using linear regression in
Excel and determined to be 0.983 and the slope of both lines were -0.625 ±0.04. Although there
was no apparent difference between the two heights, either position could be used for this
analysis. We decided to use a probe height of 4 mm for all additional experiments.

Legend: Error bars represent 1 standard deviation
Figure 4.4: Percent reflectance at 980 nm plotted for probe positioned at 3 mm and 4 mm
above the dried blood spot for samples prepared at 25%, 55% and 75% hematocrit, samples
analyzed in triplicate
4.3.3 UV reflectance analysis of control samples
Reflectance measurements were made for control samples prepared at 25%, 35%, 45%, 55%,
65% and 75% hematocrit. Samples were analyzed in triplicate at different positions on a dried
blood spot. In addition three different lots of Whatman 903 filter paper and one lot of DMPK
filter paper were analyzed. UV spectra from 200 nm to 1000 nm was collected for each sample
to generate UV reflectance spectra, Figure 4.5. The reflectance measurements for samples with
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different hematocrits do have some distinct features as referenced by Serebrennikova
(Serebrennikova, Smith, Huffman, Leparc, & García-Rubio, 2008). Also, there were two distinct
bands at 540 nm and 570 nm which have been previously reported as characteristic
hemoglobin bands (Yu et al., 2008; Zijlstra et al., 1991). The region above 800 nm has few
distinct features and provides a relationship between hematocrit and reflectance.

Legend: UV reflectance measurements for dried blood spot samples at various hematocrit levels as
indicated. Blank is a blank newborn screening card. Distinct hemoglobin bands can be seen at 540 nm
and 570 nm.

Figure 4.5: UV/NIR reflectance spectra for dried blood spots prepared at various levels of
hematocrit and an absorbance spectra for a blank Whatman 903 filter paper sample
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Data analysis of the UV reflectance spectra was performed by extracting percent
reflectance at different wavelengths and plotting the signal response versus percent
hematocrit. Several wavelengths show a linear correlation between percent hematocrit and
hemoglobin; however 980 nm showed the best correlation and had the largest slope. Since the
slope is the sensitivity of the analysis the linear relationship with the largest slope was chosen.
Dried blood spots prepared at various levels of hematocrit were evaluated on two additional
lots of Whatman 903 filter paper and on lot of DMPK filter paper cards. Acceptable, linear
relationships with correlation coefficients greater than 0.9939 were observed for each set of
samples, however there did appear to be slight differences between the reflectance response
for samples prepare with DMPK filter paper and the Whatman 903 filter paper (Figure 4.6).
This difference may be related to the volume of blood spotted on the DMPK filter paper cards
was only 15 µL , where the volume of blood spotted on the Whatman 903 filter paper cards was
50 µL. It has been previously reported that volume of blood spotted on filter paper affects the
volume of sample analyzed from a 6 mm punch (Mei et al., 2001).
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Legend: Three different lots of Whatman 903 filter paper (Squares, Diamonds and Triangles)
One lot of DMPK filter paper (Circles). Error bars represent 1 standard deviation
Figure 4.6: Plot of reflectance measurement at 980 nm versus hematocrit for control samples
prepared at different levels of hematocrit on three different lots of Whatman 903 filter paper
and one lot of DMPK filter paper, samples analyzed in triplicate each measurement made at a
different location on the dried blood spot
The average response for each hematocrit level on the three different lots of Whatman
903 filter paper was used for our model. A linear model was achieved between percent
reflectance and hematocrit with an overall correlation coefficient 0.9933. This model was used
to calculate the percent hematocrit for the donor samples at low, normal and high hematocrit
levels.
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Legend: Error bars represent 1 standard deviation from the average of three different lots of
Whatman 903 filter papers.
Figure 4.7: Plot of the average reflectance at 980 nm versus hematocrit for control samples
prepared at different levels of hematocrit on three different lots of Whatman 903 filter
paper, each filter paper lot was analyzed in triplicate
4.3.4 Evaluation of sample volume on reflectance
The volume of blood spotted has also been shown to affect the sample size (Mei et al.,
2001). When spotting small volumes (15 µL) of blood the percent hematocrit has been shown
to have less effect on sample size (Denniff & Spooner, 2010). However the sample volume can
increase by as much as 15% between 25 µL of blood spotted and 125 µL of blood spotted on
filter paper (Mei et al., 2001). Therefore we decided to investigate the reflectance
measurement for samples that were prepared with different volumes of blood. Samples
prepared with 10 µL, 25 µL 50 µL and 100 µL at 35%, 55% and 65% hematocrit were analyzed
118

using UV reflectance at 980 nm. Samples were analyzed in triplicate for each volume and
hematocrit level at various positions on dried blood spots, results are shown in Figure 4.8.

Legend: Error bars represent 1 standard deviation.
Figure 4.8 Plot of blood volume spotted on Whatman 903 filter paper cards versus reflectance
measurements at 980 nm for blood containing 35%, 55% and 65% hematocrit, dried blood
spots were prepared by spotting 10 µL, 25 µL, 50 µL and 100 µL of blood on filter paper,
samples were analyzed in triplicate
It is apparent from Figure 4.8 that as the volume of sample spotted on the filter paper
increases there is a decrease in the percent reflectance. Also the decrease in reflectance is not
consistent from 35% hematocrit to 65% hematocrit, as shown by the slope of the lines -0.033
and –0.066 respectively. Samples prepared with 65% hematocrit showed the largest decrease
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in reflectance as the volume of blood spotted increased from 10 µL to 100 µL. Using just
reflectance alone, it would not be possible to distinguish between a 10 µL sample with a 65%
hematocrit spotted and 100 µL sample with a 55% hematocrit. However, 50-100 µL of blood
spotted have differences between 35%, 55% and 65%. The manufacture indicates that the
amount of blood that will fill the circular region on a dried blood spot is between 75 to 100 µL
of blood.
4.3.5 Evaluation of hematocrit in donor samples
In order to evaluate the accuracy of our model donor samples prepared at low, normal
and high hematocrits were evaluated with UV reflectance. Each dried blood spot was analyzed
in triplicate at different positions to test the intra spot variability. Reflectance data was
collected for each sample from 200 nm to 1000 nm for each sample. The response at 980 nm
was used to back calculate the hematocrit level using our model, shown in Figure 4.7. Results
from this experiment are presented in Table 4.2, along with the predetermined hematocrit
levels and the percent difference from our measured value. The overall percent hematocrit
determined using UV reflectance was within + 11% of the measured value. In addition, the
overall percent relative standard deviations for three replicate measurements at three
hematocrit levels were within 11%.
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Table 4.2: Determination of hematocrit for donor samples using reflectance at 980 nm.
Low Level
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
Rep 1
32
35
39
24
30
24
Rep 2
28
33
39
25
32
24
Rep 3
32
34
42
23
34
24
Mean
31
34
40
24
32
24
S.D.
2
1
2
1
2
0
%RSD
7%
4%
5%
5%
6%
1%
Measured Hematocrit
29
34
36
25
32
27
% Difference from Measured
6%
0%
11%
-6%
0%
-11%
Normal Level
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
Rep 1
49
52
50
39
47
37
Rep 2
49
49
48
38
45
38
Rep 3
48
54
52
41
50
35
Mean
49
51
50
39
47
36
S.D.
0
2
2
2
2
1
%RSD
1%
5%
4%
4%
5%
4%
Measured % Hematocrit
46
51
50
38
48
41
% Difference from Measured
6%
1%
0%
4%
-2%
-11%
High Level
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
Rep 1
76
64
71
65
58
69
Rep 2
69
73
73
70
68
67
Rep 3
64
79
68
64
59
61
Mean
69
72
70
66
62
66
S.D.
6
8
3
3
6
4
%RSD
9%
11%
4%
5%
9%
6%
Measured % Hematocrit
66
71
71
68
67
68
% Difference from Measured
5%
0%
-1%
-3%
-8%
-4%

4.4 Quantitative analysis
4.4.1 Quantitative analysis of control samples to determine sample volume
Quantitative analysis of the dried blood spots was used to evaluate the relationship
between sample volume and hematocrit. There have been others that have evaluated this
relationship for selected pharmaceutical compounds and for amino acids and acylcarnitines for
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dried blood spots at various hematocrit levels. We are reporting data for a wider range of
hematocrit than was previously reported. And it was necessary to establish measurements
based on our samples to show the relationship between UV reflectance and sample volume.
For this experiment, a 3.0 mm punch from dried blood spots using samples prepared
with 50 µL of whole blood spotted on Whatman 903 filter paper. Samples were extracted in
0.100 mL of a mixture of 90:10 acetonitrile/water with 10 mM ammonium formate and
analyzed by LC/MS/MS for acylcarnitines using a HILIC Amide (2.1 x 50 mm, 1.7 µm) column at a
flow rate of 0.3 mL/minute. Compounds were eluted using a gradient elution form 95% B to
55% B over 3 minutes with 90:10 acetonitrile/10 mM ammonium acetate for mobile phase B
and 0.1% formic acid in water for mobile phase A. Multiple reaction monitoring (MRM) of 12
acylcarnitines was performed on a Waters Premier mass spectrometer with positive
electrospray ionization, with optimized MRMs shown in Table 4.1. Samples were quantified
using an external calibration curve prepared in 90:10 Acetonitrile/ 10mM ammonium formate
containing Carnitine, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16, C18.
Dried blood spot samples from each of the three lots of Whatman 903 filter paper were
analyzed in triplicate at each hematocrit level from 25% to 75%. Back calculated values of each
analyte were determined using the external calibration curve. The volume of the sample was
determined based on the fortified level and back calculated concentration using Equation 4.1:
Equation 4.1: Calculation for sample volume from an extracted dried blood spot sample
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Sample volume was calculated for each analyte Carnitine, C2, C3, C4, C5, C6, C8, C10, C12, C14,
C16 and C18, since it was previously reported that some analytes appear to have a
chromatographic effect on the filter paper cards. Although there were some differences
observed in the sample volume when calculated using different analytes the overall differences
were less than 10%. The volume for each hematocrit level was calculated by averaging the
results obtained from all the analytes. The overall % relative standard deviations were less than
10%. Results for the average volume verses hematocrit determined on the three lots of
Whatman 903 filter paper are shown in Figure 4.9.

Legend: Error bars represent 1 standard deviation.
Figure 4.9: Plot of sample volume versus hematocrit for dried blood spots analyzed from a 3.0
mm punch, sample volume calculated using quantitative analysis of Carnitine, C2, C3, C4, C5,
C6, C8, C10, C14, C16, C18 for 3 different lots of Whatman 903 filter paper, each data point
represents the average volume calculated using the all the analytes and each sample was
analyzed in triplicate
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It was apparent from our results that as the percent hematocrit increases there is an
increase in sample volume. There is approximately a 55% increase in sample volume from 25%
hematocrit to 75% hematocrit. The three different lots of Whatman 903 filter paper cards
showed consistent results for each of the different hematocrit levels. The overall average from
the three different lots of Whatman 903 filter paper were used to determine the average
volume for each hematocrit level. A linear correlation with a slope of 2.42(+ 0.14), a y-intercept
of 1.58 (+0.07) and a coefficient of determination (R2) of 0.9860 was obtained, Figure 4.10. This
curve was used to determine sample volume of the donor samples based on the response from
the reflectance measurements.

Figure 4.10: Plot of the average volume from a dried blood spot calculated from quantitative
analysis of Carnitine, C2, C3, C4, C5, C6, C8, C10, C14, C16, C18 from a 3 mm punch using 3
different lots Whatman 903 filter paper versus hematocrit from 25% to 75%.
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4.4.2 Quantitative analysis of donor samples
Eighteen donor samples at high, normal and low hematocrit levels were extracted using
the same conditions as described earlier. Back calculated concentrations were determined for
each acylcarnitne C0, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16 and C18 using response ratios
with labeled internal standards. Analyte concentrations were first calculated using assuming
the sample volume extracted was 3.1 µL from a 3 mm punch. Table 4.3 shows the calculated
accuracy for each analyte based on the known fortified concentration. The average accuracy for
individual acylcarnitines in the low hematocrit samples ranged from 67% to 82% for an overall
accuracy of 76% ± 4%. The average accuracy for individual acylcarnitines in the high hematocrit
samples ranged from 94% to 136% for an overall accuracy of 110% ± 10%.
Next the same data was recalculated with the appropriate volume using the hematocrit
determined from the reflectance measurements reported in Table 4.2. Sample volumes were
calculated for the hematocrit level in each sample using the equation in Figure 4.10. Using the
volume correction the accuracy was determined Table 4.4 shows the calculated accuracy for
each analyte based on the known fortified concentration. The average accuracy for individual
acylcarnitines in the low hematocrit samples ranged from 97% to 114% for an overall accuracy
of 103% ± 5%. The average accuracy for individual acylcarnitines in the high hematocrit
samples ranged from 81% to 115% for an overall accuracy of 98% ± 8%.
Overall there was a negative bias of 24% for low hematocrit samples when volume of
the excised samples was not corrected for volume based on hematocrit. There was a slight
positive bias of 10% observed for samples at high hematocrit when the excised sample was not
corrected for volume based on hematocrit. However when sample volumes were corrected for
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hematocrit that was determined by using our reflectance technique the overall bias was
reduced to less than 3%. In addition correcting for sample volume improved the precision of
the analysis by reducing the percent relative standard deviations from 18.7% to 11.7%.
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Table 4.3: Calculation of percent accuracy for acylcarnitines in 6 donor samples at low,
normal and high hematocrit. Samples not corrected for volume.
Donor

C0

C2

C3

1
2
3
4
5
6
Mean
S.D.
%RSD
Overall

78%
81%
89%
66%
81%
67%
77%
8.8%
11.5%
76%

65%
74%
81%
65%
72%
44%
67%
12.5%
18.7%

69%
75%
83%
67%
79%
64%
73%
7.5%
10.3%

1
2
3
4
5
6
Mean
S.D.
%RSD
Overall

1
2
3
4
5
6
Mean
S.D.
%RSD
Overall

C0

C2

C3

88%
84%
93%
75%
87%
68%
82%
9.4%
11.4%
87%

95%
98%
103%
87%
98%
68%
91%
12.7%
13.9%

93%
89%
99%
83%
95%
74%
89%
8.9%
10.1%

C0

C2

C3

94%
96%
101%
95%
92%
86%
94%
4.8%
5.2%
110%

142%
138%
141%
143%
128%
125%
136%
7.8%
5.7%

115%
114%
121%
119%
120%
113%
117%
3.5%
3.0%

Donor Samples at Low Level Hematocrit
C4
C5
C6
C8
C10
C12

C14

C16

C18

74%
76%
90%
73%
79%
73%
78%
6.6%
8.6%

83%
80%
91%
75%
85%
78%
82%
5.6%
6.8%

76%
79%
89%
70%
82%
72%
78%
6.8%
8.7%

77%
79%
86%
73%
83%
72%
78%
5.5%
7.0%

Donor Samples at Normal Level Hematocrit
C4
C5
C6
C8
C10
C12

C14

C16

C18

95%
85%
93%
82%
96%
81%
89%
6.9%
7.7%

87%
82%
98%
83%
99%
80%
88%
8.3%
9.4%

94%
83%
96%
85%
96%
82%
89%
6.7%
7.5%

86%
84%
98%
82%
95%
76%
87%
8.1%
9.3%

86%
85%
95%
81%
93%
76%
86%
7.1%
8.2%

Donor Samples at High Level Hematocrit
C4
C5
C6
C8
C10
C12

C14

C16

C18

114%
101%
113%
111%
110%
99%
108%
6.2%
5.7%

108%
101%
110%
116%
102%
99%
106%
6.8%
6.4%

106%
98%
103%
111%
97%
95%
102%
6.4%
6.3%

79%
80%
86%
70%
81%
74%
78%
5.6%
7.1%

109%
108%
114%
113%
122%
120%
114%
5.5%
4.8%

77%
78%
85%
68%
80%
72%
77%
5.9%
7.7%

90%
84%
92%
76%
91%
78%
85%
6.9%
8.1%

108%
107%
110%
112%
112%
115%
111%
2.8%
2.5%

75%
76%
84%
64%
73%
69%
73%
6.6%
9.0%

87%
81%
92%
76%
90%
73%
83%
8.0%
9.6%

110%
100%
107%
105%
105%
111%
107%
3.8%
3.6%
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78%
79%
89%
68%
81%
73%
78%
7.2%
9.2%

90%
84%
97%
83%
92%
77%
87%
7.2%
8.3%

113%
106%
115%
114%
112%
110%
112%
3.3%
2.9%

75%
76%
82%
70%
76%
72%
75%
4.2%
5.5%

83%
74%
87%
79%
85%
76%
81%
5.2%
6.4%

102%
95%
108%
100%
104%
98%
101%
4.4%
4.3%

118%
108%
118%
117%
109%
106%
113%
5.5%
4.9%

Table 4.4: Calculation of percent accuracy for acylcarnitines in 6 donor samples at low,
normal and high hematocrit. Samples corrected for volume using reflectance measurements
Donor

C0

C2

C3

1
2
3
4
5
6
Mean
S.D.
%RSD
Overall

111%
111%
113%
112%
119%
118%
114%
3.6%
3.1%
103%

97%
107%
106%
117%
111%
83%
104%
11.7%
11.3%

92%
96%
99%
100%
105%
94%
98%
4.7%
4.8%

Donor

C0

1
94%
2
89%
3
102%
4
115%
5
100%
6
94%
Mean
99%
S.D.
8.8%
%RSD 8.9%
Overall 98%

C2
102%
105%
114%
97%
115%
98%
105%
7.7%
7.3%

C3

Donor Samples at Low Level Hematocrit
C4
C5
C6
C8
C10
C12
104% 101%
102% 98%
102% 101%
102% 98%
106% 104%
107% 103%
104% 101%
2.2% 2.4%
2.1% 2.3%

C0

C2

C3

1
2
3
4
5
6
Mean
S.D.
%RSD
Overall

77%
79%
84%
83%
85%
76%
81%
4.0%
4.9%
98%

111%
112%
115%
123%
118%
108%
115%
5.5%
4.8%

101%
99%
106%
108%
114%
103%
105%
5.5%
5.3%

103%
100%
105%
99%
105%
105%
103%
2.9%
2.8%

98%
96%
97%
101%
98%
104%
99%
2.8%
2.9%

96%
89%
98%
94%
100%
96%
96%
3.9%
4.1%

94%
84%
98%
97%
99%
90%
94%
5.7%
6.0%

97%
88%
103%
121%
101%
94%
101%
11.1%
11.0%

89%
78%
93%
105%
94%
94%
92%
8.8%
9.5%

94%
86%
104%
108%
108%
98%
100%
8.8%
8.8%

Donor Samples at High Level Hematocrit
C4
C5
C6
C8
C10
C12
97%
94%
101%
104%
116%
110%
104%
8.3%
8.0%

97%
98%
94%
88%
97%
95%
102% 96%
107% 101%
106% 103%
100% 97%
5.4% 5.1%
5.4% 5.3%
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101%
93%
102%
104%
107%
102%
102%
4.9%
4.8%

91%
83%
95%
91%
99%
91%
92%
5.2%
5.7%

C16

C18

97% 108% 102% 104%
97% 101% 102% 104%
106% 107% 106% 103%
105% 108% 108% 111%
103% 110% 110% 111%
104% 112% 109% 109%
102% 108% 106% 107%
4.1% 3.7% 3.4% 3.9%
4.0% 3.4% 3.2% 3.6%

Donor Samples at Normal Level Hematocrit
C4
C5
C6
C8
C10
C12

101% 102%
93%
90%
105% 99%
99%
95%
105% 106%
93% 100%
99%
99%
5.3% 5.7%
5.4% 5.8%

Donor

98%
96%
99%
93%
95%
99%
97%
2.4%
2.5%

C14

C14

C16

C18

101% 93%
93%
87%
88%
89%
102% 105% 102%
106% 108% 102%
105% 105% 104%
101% 97%
98%
100% 99%
98%
6.9% 7.8% 5.6%
6.8% 7.9% 5.7%

C14

C16

C18

105% 102% 95%
92%
94%
89%
87%
84%
105% 100% 96%
90%
107% 102% 105% 100%
104% 105% 97%
92%
98%
91%
90%
86%
102% 98%
95%
91%
4.8% 6.4% 6.0% 5.8%
4.7% 6.6% 6.4% 6.3%

4.5 Conclusions
We have developed a novel approach that allows for the determination of hematocrit
directly on dried blood spots using reflectance. In addition, we have shown that the sample
volume is dependent on the percent hematocrit and can be used to correct for sample volume.
Donor samples at various hematocrits were used to test both models and demonstrated
acceptable precision and improved accuracy over the standard technique which assumes that
all samples are 3 µL. The ability to predetermine the hematocrit directly on dried blood spots
using UV reflectance can be used to correct for sample volume, improving the accuracy of this
sample collection technique. Correcting for volume greatly improves the accuracy of analysis
and the reflectance format used allows for direct automatable volume corrections on the card
without the need for off line procedures to test whole blood.
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CHAPTER 5

SUMMARY AND OVERALL CONCLUSIONS

According to the CDC there are over 4 million children born every year in the United
States. It is a state mandated requirement that all of these children be tested for inheritable
metabolism disorders, endocrinopathies, hemoglobinopathies and genetic disorders. Dried
blood spot analysis has been pivotal to newborn screening, since it is an extremely cost
effective way of collecting, shipping and storing samples. It has been more than 50 years since
dried blood spots were developed for the analysis of PKU by Robert Guthrie and newborn
screening has grown to test for more than 40 metabolism disorders. Although this testing
program has been claimed to be one of the most successful public health programs, there is an
increasing need to further improve this testing. Newborn screening allows for the quick
identification of disorders; however the current methods are not fully quantitative and often
require second-tier testing or follow-up testing by an independent laboratory to confirm a
disorder. This adds additional time to diagnosis and an increase cost to state newborn
screening laboratories and an increase cost to health care. By providing newborn screening
laboratories with new techniques and new technologies we can further improve the accuracy of
analysis, reduce costs and shorten the time to diagnosis. This is why we decided to investigate
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new approaches to dried blood spot analysis using automation and high resolution
chromatography.
The first chapter of this dissertation covers the background to newborn screening dried
blood spot analysis for the identification of metabolism disorders. Although current flow
injection approach used by newborn screening laboratories does provide a rapid screening
technique there are several potential issues with this method. In order to address some of
these issues we developed a high resolution liquid chromatographic separation that could be
conducted in approximately the same time as the current screening method. Chapter 1, also
provides a review of current techniques available for direct analysis of dried blood spots which
have been developed since the start of our research. Several of these devices have been
automated to increase efficiencies in dried blood spot analysis and minimize sample handling
requirements ultimately reducing costs and improving laboratory efficiencies. We were the first
to publish a device that allowed for direct sampling of newborn screening cards without the
need for punching disks from dried blood spots. Chapter 1, also reviews recent literature that
has investigated the affect hematocrit has on sample volume in dried blood spot analysis. It has
been reported that hematocrit has the largest effect of sample size for dried blood spot analysis
compared to volume spotted on filter paper and punch location (Mei et al., 2001). Although,
there is some controversy as to how dramatic this effect is for normal hematocrit levels there
does appear to be a significant bias of analyte concentration in samples with low and high
hematocrit.
In chapter 2, we provide a full description of our high resolution chromatographic
separation along with data supporting the method validation. We showed the ability to
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separate key isobars that are diagnostic for different metabolism disorders, which is not
possible with the current flow injection approach. We also address several key issues not
previously addressed in newborn screening such as matrix effects and quantification errors
associated with response factors. A comparison between the current newborn screening
method and our modified screening method using high resolution chromatography is outlined
in table 5.1.
Table 5.1: Comparison between the current newborn screening method used by most state
laboratories and our modified method using a high resolution chromatographic separation
Current newborn screening method
Labor intensive extraction:
1. Samples must be transferred twice
2. Requires hazardous derivatization
3. Evaporation

Modified screening method with
chromatographic separation
Fewer extraction steps:
1. Samples transferred once
2. No derivatization
3. No evaporation

Not fully quantitative:
1. Samples quantified based on single
point response factors with labeled
internal standards
2. Matrix effects could cause errors in
quantification

Improved quantification:
1. Samples quantified using internal
calibration curve encompassing a
range above and below cut-off value
2. Minimizes matrix effects by
chromatographically resolving
interferences

Poor selectivity and sensitivity:
1. No Chromatographic separation of
isobars, requires additional testing for
differential diagnosis of certain
disorders
2. Precursor ion scan and neutral loss
scan used for analysis reduces
sensitivity

Improved selectivity and sensitivity:
1. Chromatographically separates key
isomers allowing for differential
diagnosis of multiple disorders
2. Scheduled MRMs are used for analysis
improving the analyte sensitivity

Chapter 3, provides a practical application using our in-line desorption device with a
chromatographic separation. A method was developed and validated for quantification of
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leucine and isoleucine which are markers for MSUD. Our approach allowed for the direct
analysis of dried blood spots without the need for any off-line sample processing. Our
chromatographic separation is capable of resolving leucine, isoleucine and hydroxylproline, and
could be used as a rapid second tier test for MSUD. This was the first published paper that
incorporated a flow through device with a high resolution chromatographic separation.
Finally we addressed the major concern in dried blood spot analysis which is the
influence of hematocrit on sample volume. In the fourth chapter we evaluated the ability to
correct for sample volume using a hematocrit determined by direct analysis of the dried blood
spot with UV reflectance at 980nm. Our technique provides a relationship between reflectance
and hematocrit that can be used prior to sample analysis to correct sample volume. We
validated our reflectance model to determine hematocrit through the analysis of donor
samples prepared at various hematocrit levels. We also showed that sample volume is
dependent on hematocrit and is consistent from lot to lot of Whatman 903 filter paper cards.
Using both the reflectance measurement and the quantitative analysis of samples we could
relate the reflectance measurement to sample volume. To validate our technique donor
samples were analyzed at various levels of hematocrit and quantified with and without
correcting for sample volume. Correcting for sample volume showed a dramatic improvement
in accuracy at low and high hematocrit levels.
Overall we addressed several of the current issues associated with newborn screening
dried blood spot analysis. We addressed the lack of specificity in newborn screening by adding
a high resolution chromatographic separation that could be conducted in approximately the
same time as the flow injection analysis. We provided a direct analysis technique that could be
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automated increasing laboratory efficiencies which minimizes sample handling requirements.
Finally, we addressed a major concern which was how to correct for differences in hematocrit
by applying UV-NIR reflectance as a means to directly analyze dried blood spots to determine
hematocrit and relating this to sample volume. The device that we evaluated was a fiber optic
probe that allowed for direct measurements to be made to the dried blood spot. The simplicity
of this device and the use of fiber optics would allow for it to be easily integrated by newborn
screening laboratories. These improvements that we have investigated could dramatically
improve the efficiencies and accuracy of newborn screening dried blood spot analysis.
Although our research does provide significant improvements to the newborn screening
methodology we were not able to test our methodologies with incurred samples from real
newborns. This is due to the limited availability of newborn screening samples and potential
controversies associated with analysis of samples from other laboratories. We believe the next
step to this research would be to apply our methods in parallel with the current methods using
incurred samples from newborns. Future work could also investigate the ability to add
additional markers to the high resolution chromatographic separation. This would allow for
more accurate diagnosis of disorders that have more selective markers available for
identification such as methylmalonic acid for methylmalonic acidemia (MMA). Also, several inline desorption devices are now commercially available and could be investigated for newborn
screening dried blood spot analysis with or without chromatographic separation for
identification of metabolism disorders. This would dramatically decrease the workloads of
newborn screening reducing costs and improving efficiencies. Finally the use of NIR reflectance
analysis should be evaluated with incurred samples from newborns to evaluate the potential to
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evaluate hematocrit on dried blood spots. Our approach was acceptable under controlled
conditions; however it should be further evaluated with real samples spotted as they would be
by health care providers.
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